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Abstract
Malaria is a major cause of childhood death in Africa and host genetic factors play a 
key role in determining survival from this disease. Although many candidate loci have 
been identified, there have been difficulties in confirming the significance of some of 
these loci. To some extent this might be explained by the added complexity of epistasis, 
or gene-gene interactions. Through this thesis I aimed: (1) to re-appraise a range of 
candidate malaria-association genes using a large-scale case-control study of severe 
malaria (SM) in Kilifi, Kenya; (2) to compare different approaches to detecting epistatic 
interactions; (3) to look for evidence of epistasis between candidate genes in my data 
set; (4) to examine the haplotype structure and linkage disequilibrium (LD) patterns for 
two such implicated variants (HbS and a+thalassaemia) and their gene regions, that co­
exist in the Kilifi population, and (5) to use these exemplars as a starting point for 
investigating the process of detecting epistasis in SM in a genome-wide association study 
(GWAS). Out of 71 candidate genes investigated, I observed that polymorphisms 
affecting various aspects^of red blood cells (including HBB, HBA, G6PD, FREM3, 
INPP4B, ATP2B4 and ABO) were among those associated with the strongest signals of 
differential susceptibility to SM. Because of their prominence in malaria, HbS and 
a+thalassaemia were used to illustrate interaction analysis at the GWAS level. This 
included looking at the structure of the genomic regions surrounding the genes. As 
expected, a single haplotype of approximately 200kb was seen surrounding HbS, which 
then diverged into 2 major haplotypes spanning a further 1Mb either side, an 
observation that was largely explained by ethnicity. In contrast, no marked 
LD/haplotype structure was observed in the genomic region surrounding the 
a+thalassaemia deletion, suggesting that this is a very old polymorphism. Through this 
study, I confirmed the negative epistasis seen between HbS and a+thalassaemia using a 
study design (case-control) that was different to that used previously (cohort), although 
this was not among the most significant of the interactions I detected. I searched for 
pairwise interactions between these two polymorphisms at a genome wide level using 
heterozygous and additive models for HbS and a+thalassaemia respectively. For each 
scan a single region reaching a significance level of <10~7 was found (STX18 for HbS and 
MYEOV for a+thalassaemia), plus several other novel signals were identified in the 10'6 
to 10'7 significance region. Further work will be required to validate these signals and the 
challenge will be to try and understand their biological relevance. This is now becoming 
possible with datasets in many diseases, including malaria, being released into the public 
domain. But, as this Kenyan study has shown, having large group sizes, high quality 
clinical and genetic data, it is possible to begin to explore genetic interactions in a 
disease setting.
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Chapter 1
Introduction
Abstract
In this chapter, I will describe the background to my thesis. I will start by 
describing the world malaria situation with an emphasis on Africa and in 
particular Kenya. Subsequently, I will review the life cycle of the malaria 
parasite and the main clinical manifestations of malaria. I will outline some of 
genetic principles that underlie my thesis before reviewing the literature on some 
of the host genetic factors that have been shown to play a significant role in 
determining an individual’s susceptibility to malaria that are of particular 
interest in the context of my thesis. Much of what follows will be about multi­
locus effects and explain why considering potential interactions between malaria 
candidate genes or “epistasis” might be important if we are to gain a better 
understanding of their roles in malaria pathogenesis. Finally, I will discuss the 
statistical methods that are commonly used for identifying both disease- 
association genes and gene-gene interactions and enumerate the primary 
questions that underlie the rest of my thesis.
Chapter 1
1.1 Epidemiology of Malaria
Malaria is a devastating parasitic infection of major public health concern in 
many parts of the tropical world [1]. The World Malaria Report, 2014 [2] 
estimated that around 200 million cases of clinical malaria occurred in 2013, of 
which >80% occurred in the Africa region and >90% were caused by 
Plasmodium falciparum, [2] and that the number of deaths due to malaria was
584,000 [2] of which almost 80% occurred in children aged under 5 years.
Among the 35 countries that accounted for almost 98% of the total malaria 
deaths globally, 30 were located in sub-Saharan Africa (SSA). These were: 
Nigeria, Democratic Republic of Congo, Uganda, Ethiopia, Tanzania, Sudan, 
Niger, Kenya, Burkina Faso, Ghana, Mali, Cameroon, Angola, Cote d'Ivoire, 
Mozambique, Chad, Guinea, Zambia, Malawi, Benin, Senegal, Sierra Leone, 
Burundi, Togo, Liberia, Rwanda, Congo, Central African Republic, Somalia, and 
Guinea-Bissau [3].
Pregnant women in malaria-endemic countries and non-immune travellers are 
also at high risk. Worldwide, great and varied efforts are being made to learn 
more about this disease and how to control it. Management strategies today 
include education, the development of vaccines and chemotherapeutic agents and
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vector control using approaches that include indoor residual spraying with 
insecticides and the provision of insecticide treated bed nets. Although these 
efforts have met with some success, malaria still remains a leading cause of 
morbidity and mortality, particularly in SSA [2], and parts of Asia and Latin 
America (Figure 1.1).
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1.1.1 The malaria situation in Kenya
Kenya is situated in East Africa and is bordered by Ethiopia to the north, Sudan 
to the northwest, Somalia to the east, Tanzania to the south and Uganda to the 
west (Figure 1.2). Kenya covers a total land mass of 582,646 km2, has a current 
population of 38.6 million [5] and is divided into 47 administrative counties. The 
national life expectancy is 61 years, 43% of the population are under the 15 
years and 4% aged 65 years and above [5]. The maternal mortality ratio is 360 
deaths per 100,000 live births, the infant mortality rate is 48 deaths per 1000 live 
births, and under 5 mortality is 73 per 1000 live births [6]. These rates are high 
in comparison to countries in the Western world: for example, in England and 
Wales the maternal mortality ratio was 12 per 100,000 live births, the infant 
mortality rate was 4 per 1,000 live births and the under 6 mortality was 4 per 
1000 live births in 2012 [7]. The major causes of death in children less than 5 
years of age in Kenya are neonatal causes, pneumonia, malaria and diarrhoeal 
diseases [6].
Kenya has four epidemiological zones for malaria (Figure 1.2); endemic areas 
along the shores of Lake Victoria and the coastal region where malaria 
transmission is seasonal, with peaks from June to August and again in late 
November; highland-epidemic-prone areas which are highly populated; epidemic
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prone areas in the arid and semi-arid lowlands which are sparsely populated; and 
low-risk or malaria-free areas in the highlands. Transmission in the epidemic 
prone areas is highest from April through June each year [8]. About 70% of the 
population of Kenya is at risk from malaria [9] which is responsible for about 
30% of out-patient visits (totalling more than eight million out-patient 
treatments each year), and 19% of all hospital admissions [10]. Approximately, 
14,000 children are admitted annually to a hospital due to malaria. It is also 
estimated that 6,000 pregnant women annually suffer from malaria-associated 
anaemia and that approximately 4,000 babies are born annually with low birth 
weight due to maternal anaemia. Malaria imposes a significant economic burden 
in Kenya, it is estimated that in 2009, 170 million working days were lost due to 
malaria illness [10]. Overall malaria is falling in Kenya, and this could be partly 
due to local initiatives. However, several studies show an increase in malaria 
within the epidemic-prone and low transmission zones [11]. One of the main 
study/research areas for malaria and other diseases lies on the coast north of 
Mombasa in Kilifi County (marked by the yellow circle in Figure 1.2) which falls 
within the malaria endemic zone. The malaria studies described in this thesis 
were undertaken at the KEMRI-Wellcome Trust Research Programme in Kilifi 
and are discussed in more detail in Chapter 2.
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The map is showing Kenya and the surrounding countries with international borders, the 
national capital Nairobi (the red dot) and its 47 administrative counties. The Kilifi County, 
where the sample collection took place in this thesis is marked by the yellow circle. The map 
also illustrates the malaria endemic areas within the country stratified by climatic suitability. 
Adapted from the Mapping Malaria in Africa project (www.mara.org.za).
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1.1.2 M alaria parasites and th e M alaria Life Cycle
Human malaria is caused by protozoan parasites of the genus Plasmodium. Five 
species have been recognized to cause malaria in humans: P. falciparum, P. 
vivax, P. ovale, P. malariae and P. knowlesi P. falciparum is the most 
important in SSA, accounting for the majority of deaths [12], is the only species 
of relevance in Kilifi and is therefore the focus of my thesis.
To complete its life cycle the malaria parasite requires two hosts, the definitive 
host, in which the parasite undergoes sexual development (a female mosquito), 
and an intermediate host; anopheles mosquitoes and humans in the case of 
human malaria. Figure 1.3 illustrates the life cycle of Plasmodium species using 
P. falciparum as an example. The infection starts when a female mosquito 
begins to feed on a human host. Sporozoites are injected from the salivary glands 
into the dermis of the human from where they make their way into the blood 
vessels. The sporozoites then travel to the liver where they invade hepatocytes 
and multiply [13]. After about 10 days the hepatocytes rupture, releasing 
thousands of merozoites into the bloodstream. The merozoites rapidly invade the 
red blood cells (RBCs) initiating an asexual growth phase in the blood that 
leads to the clinical symptoms seen in malaria.
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Over a cycle of 48 hours, the parasite develops within the RBC from the ring to 
trophozoite stage before replicating asexually to form schizonts composed of 
twelve to twenty-four merozoites. Lysis of the red cell releases the merozoites 
which invade fresh RBCs to start the next cycle [13]. A small sub-set of the 
invading merozoites develop into gametocytes (male and female), which are 
taken up by feeding Anopheline mosquitoes. Gametocytes combine sexually in 
the mosquito mid-gut before developing sequentially into zygotes, ookinetes and 
then oocysts in the gut wall. These burst into the mosquito haemocoel releasing 
sporozoites that migrate to the salivary glands to await inoculation into the 
human host at the next blood meal [13].
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1 .1 .3  T h e  c l in ic a l  m a n i f e s t a t io n s  o f  m a la r ia
Tlie clinical outcomes of P. falciparum infection range from asymptomatic 
infection to severe disease and death. In many malaria-endemic regions of Africa, 
the majority of individuals carry P. falciparum parasites during the high malaria 
transmission season. While most individuals are asymptomatic or display only 
mild symptoms of malaria disease such as fever, headache, nausea, vomiting and 
cough, 1-2% of infections progress to severe and potentially fatal complications 
[14]. The diagnosis of malaria is based on clinical criteria supplemented by the 
detection of parasites in the blood [15].
1.1.3.1 Severe malaria
The WHO defines severe malaria (SM) as one or more of the following 
symptoms in a patient with P. falciparum malaria: prostration (a Blantyre coma 
score (BCS) of 3 or 4), cerebral malaria (CM) (a BCS of <3), multiple seizures 
(two or more seizures within 24 hours prior to admission), severe malaria 
anaemia (SMA) (haemoglobin <5g/dl or a haematocrit <15% in association 
with a parasitaemia >10,TTI/t ' of blood) or respiratory distress (RD) 
(abnormally deep breathing).
The most common clinical manifestations of SM in childhood are SMA, CM and 
RD [16]. SM is almost exclusively caused by P. falciparum and is a major cause
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of childhood hospital admission and death in endemic areas [17]. The frequency, 
pattern and distribution of severe forms of P. falciparum malaria differ 
depending on the transmission areas [18, 19]. A patient with SM symptoms has 
a high chance of dying, but this depends on a range of factors that include host 
genetic makeup, background immunity, age and access to clinical care [20].
1.1.3.2 Severe malarial anaemia
The greatest burden of SMA is carried by young children and pregnant women 
[21]. Mortality from anaemia is about 1% when occurring alone but increases 
rapidly (up to 35%) when occurring in combination with other severe 
complications including CM or RD as shown in Figure 1.4 [22]. Apart from 
malaria, other superimposed conditions may serve to increase the risk to SMA, 
including the presence of hookworm infections or iron deficiency [23]. In SSA, 
strong evidence support an age-dependent pattern of SM disease, with SMA 
being more common in infants and young children under three years and CM in 
older children [21, 24].
1.1.3.3 Cerebral malaria
Cerebral malaria is one of the most severe complications of P. falciparum 
infection.. Mostly, patients present with fever, headache, and delirium before 
progressing to an acute febrile stupor, followed by coma [25]. It is a major cause
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of mortality in P. falciparum infection. Approximately 1% of infections progress 
to CM. The majority of cases occur in SSA, and approximately 15-30% of 
individuals who develop CM die [26].
1.1.3.4 Respiratory distress
The pathogenesis of RD in patients with malaria infection is not well 
understood; it is most commonly thought to be a clinical manifestation of 
metabolic acidosis and is associated with a mortality of approximately 24% [22]. 
Mortality increases rapidly (to >30%) when RD is found in combination with 
CM [22].
Since the purpose of genetic epidemiology in malaria is to unravel 
polymorphisms in molecular pathways that may eventually translate into new 
ways of preventing or treating the disease, SM and its sub-phenotypes (CM, 
SMA and RD) are the phenotypes of choice because they increase chances of 
detecting differences for most studies and the study undertaken for this thesis is 
no exception.
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1 .2  T h e  h u m a n  g e n o m e
A “genome” is an organism's complete set of deoxyribonucleic acid (DNA); 
hereditary information that is passed from generation to generation. DNA 
molecules are made of a pair of twisted strands. Each strand consists of a sugar- 
phosphate backbone with units called “nucleotide bases” hanging off it. There 
are 4 forms of bases: adenine (A), thymine (T), cytosine (C) and guanine (G), 
and the human genome can be considered as a very long sequence consisting of 
approximately 2.9 billion nucleotides, each denoted by the letter of its names, 
e.g. ATCCGA. The two strands are held together by primarily hydrogen 
bonding between the bases. Adenine is always paired with T and C is always 
paired with G, actually both strands contain the same information. These paired 
nucleotides are called “base pairs ”.
The main function of DNA is to act as a template for the production of proteins, 
which are functional units participating in most cellular processes. In the nucleus 
of each cell, the DNA molecule is packaged into thread-like structures called 
“chromosomes”. The human genome comprises 23 pairs of chromosomes as 22 
pairs of autosomes and one pair of sex chromosome (a female has two X- 
chromosomes whereas a male has one X and one Y sex chromosome): 46 
chromosomes in total. Because the autosomal chromosomes are arranged in
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pairs, they are called “homologous” chromosome pairs. In each pair, one of the 
chromosomes is inherited from the mother and the other from the father. A 
“sex chromosome” is a type of chromosome that participates in sex 
determination. A specific location along a given chromosome, or a specific 
position in the genome, is called a “locus”. The term “gene” is sometimes defined 
as a segment of DNA within a chromosome that specifies the amino acid 
sequence for a peptide/protein.
The majority of DNA is similar between the genomes of all humans. 
Nevertheless, due to changes in the nucleotide sequences of DNA molecules that 
have occurred during population history, there is variability at millions of 
locations in the genome. There are several types of such variation, commonly 
called “polymorphisms”. Of these, the most common are “single nucleotide 
polymorphisms” (SNPs), which are characterised by single base changes in DNA 
sequence. Figure 1.5 is an illustration of DNA, gene and SNP in a chromosome 
in the genome. The alternative DNA sequences at a locus, or different “versions” 
of the same gene, are known as “alleles”. A “reference” allele for a given locus 
refers to the wild type or the ancestral while a “derived ” allele is an allele that 
arises in the evolution due to a mutation. For a given polymorphism, the 
combination of alleles from two chromosomes determines the “genotype” of the
1.2 The human genome
individual. The “homozygous” genotype is when two alleles are identical (i.e. 
AA), and “heterozygous” genotype is when the alleles are different (i.e. AT).
A combination of alleles at different loci on a chromosome that are inherited 
together is referred to as a “haplotype”. Linkage disequilibrium (LD) is the 
correlation or non-random association of alleles at adjacent loci. When a 
particular allele at one locus is found together on the same chromosome with a 
specific allele at a second locus more often than expected if the loci were 
segregating independently in a population, the loci are in LD.
Many types of polymorphism occur but the most common after SNPs are 
“insertion/deletion” of one or more base pairs from the sequence, “inversions”, 
arrangements in which order of the DNA sequence is reversed in a specific 
chromosomal region, among others “copy number variants”, segments of DNA 
which are present at a different copy number compared to the reference genome. 
Further details regarding these concepts and terminologies can be found in 
review papers such as Olson et al. [28].
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1.3 Host genetics factors and malaria
Malaria has been a major cause of mortality since ancient times [30] and, as a 
result, it has been a powerful selective driving force in humans as both parasite 
and host have evolved to increase biological fitness through natural selection. 
The variations that have occurred in the human genome over multiple 
generations to yield so-called ‘malaria protective genes’ are not only of scientific 
importance but are also biologically important due to their impact on health.
While numerous candidate genes have been screened for their involvement in 
malaria disease severity [31], most have been investigated in small studies.
A longitudinal survey of twin children in The Gambia [32] was one of the first 
genetic studies to address the question of genetic determinants of susceptibility 
to clinical malaria. In this study, the authors compared the incidence of clinical 
malaria in pairs of twin children within families who shared the same 
environmental exposure. The monozygotic twins (children derived from a single 
zygote who are therefore genetically identical) were both found more likely to 
have a malaria fever attack than dizygotic twins (children derived from two 
zygotes), signifying a role of host genetic factors on disease burden.
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The contribution of genetic and non-genetic factors towards SM was also 
examined in a Sri Lankan population, which was one of the first genetic studies 
to quantify the contribution of genetic factors to susceptibility to clinical malaria 
[33]. The heritability was approximately 15% for the incidence of both P. 
falciparum asymptomatic and symptomatic infections, and around 10% for the 
intensity of clinical symptoms. Through a similar study, it has been estimated 
that 34% of the total variation in both uncomplicated and hospital-admitted 
malaria in two cohorts of Kenyan children was explained by additively acting 
host genes [34]. However, sickle cell trait (HbAS), the most prominent of the 
malaria-protective polymorphisms identified to date only counted for around 2% 
of this variation [34], suggesting that more malaria protective genes remain to be 
discovered. In a subsequent study conducted in Thailand similar observations 
have been made, where the contribution of genetic factors to the variability in 
the incidence of uncomplicated P. falciparum and P. vivax malaria infections in 
a large cohort of mixed ages was found to be 10% and 19% respectively [35].
A wide range of other candidate genes have been demonstrated to confer 
protection against SM as summarised in Table 1.1. For example, genetic variants 
of (3-globin: HbS [36], HbE [37], HbC [38]; a-globin [39-41]; enzymopathies (e.g. 
glucose-6-phosphate dehydrogenase deficiency) [42, 43]; structural variants of red
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cell membrane proteins (e.g. band 3 protein (AE1) [44], ATP2B4 [45], HLA) [46] 
and several cytokine loci (e.g. Tumor Necrosis Factor-alpha [47-49], Interleukin- 
12 [50], Interferon-alpha receptor- 1 [51], Interleukin-4 [52]). Nevertheless, the 
majority of these studies have been small, and some of them have yielded 
conflicting results.
With recent advances in genotyping technologies and analyses using advanced 
molecular biology software, it is likely that the already large panel of host 
genetic factors will expand and thereby also increase the likelihood of identifying 
true associations. In this thesis, I seek to confirm some of the above reported 
associations using a large case-control study of SM conducted in Kenya. The 
results of this study are presented in Chapter 3. In the sections that follow, I will 
discuss some of the haemoglobinopathies (disorders of the haemoglobin structure 
or production) that are of particular interest in the context of this thesis.
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1.3.1 Sickle haem oglobin (HbS)
The HbS variant is caused by a single base change in codon 6 of the (3-globin 
gene (HBB) that leads to the substitution of valine for glutamate within the (3- 
globin protein. The resulting variant form of haemoglobin, HbS, tends to 
polymerise under conditions of low oxygen tension, becoming insoluble and 
causing distortion of erythrocytes, which adopt a rigid 'sickle' shape [138]. The 
carrier form (heterozygote - one normal (HbA) and one abnormal (HbS) copy of 
the HBB gene) of HbS referred to as sickle cell trait (HbAS) was among the first 
genetic conditions to be associated with malaria protection more than 60 years 
ago [17, 139, 140]. I will further elaborate in detail this polymorphism and its 
relationship with SM in subsequent Chapters.
1.3.2 Thalassaem ia
The thalassaemias are inherited conditions of haemoglobin that are manifested 
by decreased or zero production of the a -  or (3-globin proteins that are required 
for the formation of haemoglobin. Unlike HbS, the thalassaemias do not affect 
the structure of the globin protein itself, but according to its form, leads to 
deficient or absent synthesis of a— or (3-globin chains. Alpha-thalassaemia occurs 
when one or more copies of the paired a-globin genes on chromosome 16 are 
missing, most commonly due to the inheritance of deletions within HBA [38].
1.4 Approaches for detecting association in genetics studies
Alpha-thalassaemia is found at high frequencies in many parts of Africa, South 
and South-east Asia and the Pacific, as well as in African descendants in South 
and Central America. In some countries (most notably Nepal and Papua New 
Guinea) the prevalence of a +thalassaemia approaches 80%, while in SSA 
prevalence does not usually exceed 50% [141]. Beta-thalassaemia, on the other 
hand, results from defects in the HBB  gene on chromosome 11 that encode the 
production of the beta globin protein [120]. Beta-thalassaemia is prevalent in the 
Mediterranean region including the coastal areas of Turkey, Greece and Italy 
[142]. In our previous work in Kilifi, we found no evidence of P-thalassaemia in 
our population [143] therefore, in this thesis I will only focus on a +thalassaemia.
1.3.3 The ABO  B lood group system
The ABO blood type was first discovered in 1900 by Karl Landsteiner [144]. The 
ABO blood group system is the most important RBC polymorphism due to its 
significant role in successful blood transfusion and organ transplantation [145]. 
The system is split into 3 groups called A, B and O. These groups are defined on 
the basis of the composition of the oligosaccharides bound to the H-antigen on 
the red cell surface. The O blood group lacks these oligosaccharides due to a 
non-functional transferase enzyme resulting from a frame-shift mutation, while 
blood groups A and B are the result of genetic mutation in the same transferase
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enzyme affecting its sugar specificity[146]. A is the ancestral type on which a 
polymorphism arose to create B. Then later a further mutation arose on the A 
haplotype causing a frame-shift effectively knocking-out the ABO locus, this is 
the O type [147]. There are many other mutations in the ABO gene leading to 
sub-type of each of the 3 main haplotypes. Since the discovery of the ABO gene, 
numerous association studies have investigated the relationships between ABO 
blood group antigens and susceptibility, resistance, or severity of P. falciparum 
malaria disease. Some have found associations between the ABO system and 
severity of the disease, while others have reported an absence of an association 
between malaria disease and the ABO blood groups antigens [145, 148]. Chapter 
3 of this thesis describes the results of my findings.
1.3.4 G lucose-6-phosphate dehydrogenase (G 6P D ) deficiency
G6PD is a housekeeping enzyme that functions as an antioxidant, and thus 
protects the cells from oxidative damage. The G6PD gene is located on the X 
chromosome. Many allelic variants are found at this locus, two of which can 
reach frequencies of up to 20% in populations from Africa and the 
Mediterranean [149]. These 2 alleles are known as G6PD c.202G>A (rsl050828) 
and G6PD c.376A>G (rsl050829) and together fall into the A- WHO 
classification scheme (the A being an electrophoretic mobility shift due to 376G
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and the minus being a decrease in enzyme activity driven by 202A). This pair of 
alleles (as a haplotype) is the cause of the commonest G6PD deficiency in SSA 
exhibiting about 12% of normal enzyme activity (or B type in the same WHO 
classification) [150]. Since this disorder is sex-linked (females have 2 copies of the 
gene and males one copy (hemizygous)), it affects almost exclusively males; 
however, homozygous females are also affected and heterozygous females can 
also suffer from haemolytic anaemia induced by G6PD deficiency because of 
unequal Lyonisation. In both G6PD hemizygous males, and homozygous females 
all enzyme copies are deficient, whereas heterozygous females pattern of the 
enzymatic deficiency is made up of a mixture of G6PD deficient and normal cells 
[116]. Like other polymorphisms, this sex-linked gene has been implicated in 
malaria protection on the basis of geographical correlation suggesting 
evolutionary selection by malaria [151]. The protection afforded by G6PD 
deficiency against SM remains debated due to conflicting results. Chapter 3 of 
this thesis describes the results of my findings from a large case-control study of 
SM in Kenya.
1.4 Approaches for detecting association in genetics studies
1.4 Approaches for detecting associations in genetics studies
A wide number of approaches can be used to investigate the relationships 
between specific genes and malaria risk including twin and adoptee studies, 
linkage studies, complex segregation analysis studies, candidate-gene studies and 
genome-wide association studies (GWAS). For the purpose of this thesis, I have 
only reviewed the last two complimentary approaches (candidate gene and 
GWAS).
1.4.1 C an d id a te  gene s tu d ies
Candidate-gene association studies depend heavily on prior information, usually 
on particular biological assumptions or the location of the candidate genes 
within a previously identified region. Polymorphisms found in these genes are 
tested for statistical association with disease in individuals enrolled in case- 
control, cohort or family studies. Variants that are found to be susceptible are 
hypothesized to influence directly an individual’s likelihood of developing the 
disease.
1.4.1.1 Case-control studies
Case-control studies are the most common in the literature. Many authors claim 
that they are the most powerful and efficient, ensuring robustness when studying 
a large number of SNPs [152]. A case-control study identifies individuals by
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disease status and tests retrospectively for exposure. Specifically, case-control 
studies in genetic analyses compare the allele frequencies or genotypes in cases 
(affected individuals) and controls (healthy individuals). Significant differences 
between the two suggest an association between the alleles being tested and a 
given disease. Most of the malaria protective genes that have been discovered to 
date have been investigated using the case-control approach. Case-control studies 
have the advantage that they are less laborious and expensive than large family 
studies. For case-control studies, a common method is to use a candidate gene 
approach but modern techniques and declining costs are increasingly allowing for 
a more genome-wide and unbiased approach.
1.4.1.2 Cohort studies
Analytically the simplest way to ascertain whether a specific allele or genotype is 
associated with risk for an infectious disease is by use of a cohort study. 
Primarily, cohorts of comparable individuals are identified who have and do not 
have a specific allele or genotype. These individuals are then followed 
prospectively for a given time to determine whether their exposure affects their 
risks of getting the disease. The measure of association between exposure and 
disease is the relative risk. The major drawback of cohort studies is the large 
sample size leading to high data collection costs.
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1.4.2 GWAS approach
Genome-wide association studies seek to identify the vast majority of common 
loci variants in the human genome that affect disease susceptibility by 
comparing allele frequencies in individuals with the disease and healthy controls. 
Since the completion of the Human Genome Project [153, 154] and HapMap 
[155, 156], genetic epidemiology has entered an era of single nucleotide 
polymorphisms. W ith the reduction in the cost and commercial availability of 
SNP genotyping, many researchers have taken advantage of these technologies, 
which has led to the publication of hundreds of GWAS seeking to find the 
genetic causes of many diseases and other traits. For example, the Wellcome 
Trust Case-Control Consortium [157], conducted association studies of seven 
common diseases (including bipolar disorder, coronary artery disease, Crohn’s 
disease, hypertension, rheumatoid arthritis, Type I and II diabetes) with a total 
of 14,000 cases and 3000 shared controls whose results were then replicated 
successfully. Since then, many important GWAS datasets have been generated in 
African populations, notable among them being studies on malaria conducted by 
the Malaria Genomic Epidemiology Network (MalariaGEN) [73, 158].
MalariaGEN is a multi-centre initiative that aims to gain a better understanding 
of the genetic epidemiology of malaria throughout the malaria-endemic world. 
Besides the likely advantages of using data generated from GWAS, such a
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network offers an opportunity for standardizing phenotype definitions, 
genotyping technology, and an experimental and analytical plan across multiple 
sites. This is anticipated to augment the power of the study as well as to ensure 
reproducibility of results, while at the same time allowing the identification and 
description of regional differences of potential biological interest.
With the above in mind, we are only just beginning to grasp how important host 
genetic factors are in determining susceptibility to malaria. The majority of 
previous reported studies have focused on the analysis of single loci; nevertheless, 
there are instances in which haplotypes rather than genotypes at a single locus 
can predict the severity of disease [159]. The fundamental difference between 
haplotypes and individual genotypes at SNPs is that the alleles are inherited 
together on a chromosome. Haplotypes can be powerful because they yield more 
information about recombination, which is the physical exchange of DNA 
molecules during meiosis (cell division). Recombination is important for locating 
disease-causing mutations by linkage methods and has a great effect on the 
extent of association between SNPs. Knowledge of the genotype at one SNP can 
predict the genotype of another SNP if the LD is high between the two SNPs. 
There has been growing interest in looking at the haplotype structure of a region 
because it will help in pinpointing the disease-causing locus by marking 
recombination events in association-based studies. This is particular pertinent in
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Africa where the high diversity of the populations results in shorter haplotypes 
therefore enhancing the likelihood of discovering causative SNPs through LD 
[160, 161]. In this thesis, I will examine the haplotype structure for two variants 
and their gene regions that co-exist in Kilifi and further investigate their LD 
pattern between the neighbouring SNPs.
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1.5 Epistasis
In genetics, epistasis is the phenomenon where one gene masks the effect of 
another [162]. Epistasis occurs if the effect of one locus affecting a complex trait 
depends on the genotype of a second locus affecting the trait. For instance, 
consider two loci (A, B), each with two alleles (A, a B, b). Epistasis would occur, 
for example, if the aabb genotype had a high disease risk, but the eight other 
possible combinations genotypes had no effect on risk. This is just one of the 
many possible forms of epistatic interaction between two loci [163]. This 
definition of epistasis is the same to the concept often used by biologists and 
molecular geneticist when investigating the interaction between proteins [164].
Epistasis and interaction refer to various aspects of the same phenomenon. The 
term ‘epistasis’ is commonly used in population genetics and refers specifically to 
the statistical properties of the phenomenon, and does not automatically imply a 
biochemical interaction between gene products. However, in broad-spectrum, 
epistasis is used to signify the departure from ‘independence’ of the effects of 
different genetic loci. Confusion often arises due to the heterogeneous 
interpretation of ‘independence’ between various branches of biology. For further 
discussion of the definitions of epistasis, and the history of these definitions, see 
[164]. For the purposes of this thesis the term epistasis remains more general;
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that is, the risk of having a phenotype can increase or decrease as a result of 
combination of two or more alleles/genes.
The presence of epistasis can have key implications for the interpretation of 
statistical models. If two loci of interest interact, the relationship between each 
of the interacting loci and a phenotype of interest depends on the genotype 
values of the two loci. In practice, this makes it more harder to predict the 
consequences of changing the value of a variable, especially if the variables it 
interacts with are hard to measure or difficult to control [165]. It is increasingly 
clear, therefore, that we will need to consider epistasis when we explore 
genotype-phenotype relationships. Failure to recognize these interactions could 
obscure important genetic loci.
A substantial number of studies in complex human diseases, including diabetes 
[166, 167] and some forms of cancer [168, 169], have shown susceptibility genes 
that contribute to a common disease trait which interact significantly with one 
another in combined analyses [170, 171]. Several investigators have found alleles 
that have opposite effects depending on the genetic background [172, 173], which 
further raises the likelihood of overlooking epistatic susceptibility genes in single­
gene analyses [174]. Other concrete examples of epistasis between genes exist 
such as interactions between Apolipoprotein E (ApoEf) and the Low-density
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Lipoprotein Receptor (LDLR) genes in coronary artery disease [175] and 
identification of gene-gene interactions for asthma susceptibility loci in three 
U.S. populations [176].
1.5.1 Epistasis betw een malaria protective genes
To date, only a small number of epistatic interactions have been investigated for 
malaria-protective polymorphisms. Most researchers have focused mainly on the 
effect of individual polymorphisms that contribute to the disease phenotype. 
However, it has been shown that co-inheritance of several polymorphisms and 
interactions between them may also play significant roles in determining 
phenotype.
1.5.1.1 HbAS and a thalassaemia
In a study conducted in Kilifi, Williams and colleagues [103] found evidence for 
epistasis in the malaria-protective effect of two important haemoglobin variants: 
HbAS and cUthalassaemia [103]. Both variants were independently associated 
with a protective effect against uncomplicated malaria as detected through an 
active community surveillance and admission to hospital with SM [103]. 
Nonetheless, this protective effect afforded by the HbAS and a +thalassaemia 
when co-inherited together was lost (see Figure 1.6) [103]. This negative epistasis
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has subsequently been confirmed in two separate populations from Ghana and 
Mali [57, 62].
1.5.1.2 Haptoglobin and cCthalassaemia
In a more recent study conducted in Kilifi, Atkinson and colleagues found 
evidence for epistasis between haptoglobin (Hp) genotype and a +tlialassaemia 
variant [177]. The protective effects against SM afforded by cCthalassaemia 
variant alone and for oCthalassaemia when co-inherited by Hp type are 
summarized in Figure 1.7. The study observed increased risk associated with 
Hp2-2 genotype group in the presence of oCthalassaemia (Figure 1.7) [177].
1.5.1.3 HbAS and G6PD deficiency
There is also some evidence of a negative interaction between HbAS and G6PD 
(A-) deficiency from a case-control study in Mali [178] where both HbAS and 
G6PD (A-) deficiency are common, occurring at frequencies of 12% and 14% 
respectively in the population. Overall, the study observed a protective effect for 
HbAS among females against SM (OR, 0.33; P=0.01); however, rather than 
experiencing additive protection, co-inheritance of HbAS and heterozygous 
G6PD (A-) deficiency in females was associated with an increased risk against 
SM (OR, 15.00; P=0.003). However, given the small number of subjects with 
these two polymorphisms the study results should be treated with caution.
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1.5.2 T he challenge o f detecting epistasis
Unlike a number of microorganisms such as budding yeast, for which epistatic 
interactions have been carefully studied through synthetic models [179], humans 
are much more challenging subjects to study. This is especially due to the high 
number of genes involved and the impracticability of conducting direct assays on 
humans (for instance, we cannot directly modify an individual’s DNA). As a 
result, analysing natural variation in genomic measurements has been the most 
feasible method for finding epistasis in humans. Nevertheless, this approach also 
poses a number of challenges, as stated below.
In order to detect epistasis in a given analytical dataset, one needs to find a pair 
or a set of markers that shows statistically significant epistatic interaction. 
Nevertheless, the number of combinations to consider increases very quickly: 
enumerating all possible pair-wise interactions among N markers requires testing 
N (N-l)/2 combinations. In the case of a GWAS study of 500,000 markers (for 
example), this requires 124,999,750,000 tests, this being just the tip of the 
iceberg if three-way interactions were to be considered. Therefore, even with the 
existence of large computing clusters, exhaustively searching for epistasis will be 
computationally challenging. In addition, testing a large number of hypotheses 
leads to a reduction in the statistical power of detecting an epistatic effect.
1.5 Epistasis
Multiple testing correction refers to a procedure that proposes stricter 
significance thresholds to counteract the rise of false positives caused by testing a 
large number of hypotheses. However, in detecting epistasis, the number of 
hypotheses is so large that any attempt to control the number of false positives 
comes at an expense of possibly losing many epistatic interactions.
1.5.3 N ovel app roaches for d e tec tin g  ep istasis
Cordell [164] provides a recent and thorough review of current epistasis analysis 
methods published in the literature as well as the potential benefits and 
drawbacks of each. The methods differ according to whether one is carrying out 
an association or linkage analysis and according to whether one is dealing with a 
‘quantitative’ or a ‘qualitative’ trait. For genetic association studies, standard 
methods for epidemiological studies may be employed, with genotypes at various 
loci considered as risk for a disease. As per the literature, commonly used 
algorithms for detecting epistasis in human complex disease are divided into two 
broad categories: those that explicitly test every possible interaction up to some 
size (exhaustive) and those that avoid an exhaustive enumeration of the 
search space (non-exhaustive). Figure 1.8 shows a diagram summarising some 
of the methods tha t can be found in the literature.
1.5 Epistasis
F igure  1.8. Classification of the methods that detect statistical epistasis.
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Most methods can be classified into two categories according to their search strategies: exhaustive 
search and non-exhaustive search. Methods in bold are described in detail in A ppendix A , Table  
A .l  while methods in blue are tested and evaluated in detail in Chapter 4.
1.5 Epistasis
1.5.3.1 Exhaustive Algorithms
An “exhaustive” method is one that enumerates all possible k-way interactions 
for some k in order to identify the effect or effects which best predict phenotypic 
outcomes. Some methods go even further, testing every possible partitioning of 
alleles. As the size of available data sets exceeds one million markers, it is 
evident that this search for interactions will present computational and 
statistical difficulties and that feasibility and the need to control for multiple 
testing needs to be taken into account.
1.5.3.2 Non-Exhaustive Algorithms
If an exhaustive method is one that searches all possible k-way interactions, a 
“non-exhaustive” algorithm performs a partial search of the possible interaction 
space to terminate relatively quickly. While they are typically faster than 
exhaustive procedures, it is impossible to know if any such method will identify 
or even test the correct solution for any given data set. Non-exhaustive 
algorithms can be further classified according to their search space reduction 
strategy. G reedy  methods perform filtering based on non-epistatic or lower- 
order interaction results to filter markers displaying no main or low-order effects. 
The success of the greedy strategy depends on the nature of interactions present 
in the data set: pure epistatic interactions displaying no main effects are likely to
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be missed. S tochastic  algorithms iteratively select a small number of loci and 
perform a thorough test for epistasis. This strategy relies on luck to select 
interacting loci in at least one iteration.
In summary, algorithms to detect multi-locus genotype-phenotype association 
may be classified as exhaustive or non-exhaustive. Members of the former 
category test all possible interactions up to a user-specified size, wliile the others 
use a greedy heuristic or stochastic search strategy to quickly identify causative 
loci. While it is beyond the scope of this thesis to describe and test all published 
methods, I have reviewed some common methods available in the literature and 
enumerated their advantages and disadvantages in detecting SNP-SNP 
interactions in A p pend ix  A , Table A .I . I have selected two representative 
algorithms: PLINK and AntEpiSeeker to explore in depth using the candidate 
gene case-control study. These, along with a novel method, are evaluated for 
statistical performance and computational efficiency in Chapter 4.
1.6 M otivation for this work
Despite various attempts to control malaria, the disease killed more than half a 
million people in 2013, the majority being children under the age of five years 
old in SSA [2]. The intriguing phenomenon about malaria is that although the 
majority of children who are exposed to repeated infection survive, only a
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relatively small proportion develops severe and life-threatening complications of 
the disease. Host genetic factors are thought to be important modifiers of severe 
and fatal malaria [34], yet insufficient is known about which genes are involved 
or the type or degree of protection that they might afford.
A wealth of host genetic association studies on malaria exists whose results have 
not been replicated in other settings. Given the complex nature of malaria and a 
number of confounding factors these variations in results are expected. One of 
the main reasons for this lack of reproducibility is the lack of statistical power in 
genetic association studies to detect these associations.
Current trends in the field of genetics are, however, revolutionizing genetic 
studies. A number of studies have revealed the complex genetics of malaria 
susceptibility and a number of genes have already been associated with malaria 
susceptibility even though the sample-size of these studies has often been too 
small. The HbAS and a +thalassaemia are the best studied of these, showing the 
greatest protection [180] and numerous mechanisms of protection having been 
proposed [181]. However, the reality that these polymorphisms are commonly co­
inherited, has received little attention [103]. Apart from the interactions seen 
between HbAS and a +thalassaemia, are there other important polymorphisms
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that interact with HbAS or a +thalassaemia to influence malaria outcome? Do 
pure interactions really exist in genetics?
W ith the sequencing of the human genome [153] and high-throughput 
genotyping technologies now available, researchers now have a set of tools that 
make it easier to find the genetic contributions to complex diseases such as 
malaria. As shown by Mackimion et al [33, 34], the genetic basis of resistance to 
malaria is expected to involve many different malaria candidate genes, 
individually resulting in only small population effects, which might be missed 
due to methodological issues such as sample size.
In recent years, I have personally gained considerable experience in my current 
role as a MalariaGEN Data Fellow including how to prepare and analyse genetic 
data and how to conduct a number of different bioinformatics and statistical 
analyses. I have spent some of my efforts in developing a resource for analysing 
the associations between published genetic markers and SM in children in the 
study area. This data will not only be the first and most detailed genetic data 
for Kilifi, but also serve as quality control data for further studies to be 
conducted in the area. In addition the study will shed more light on the 
replication or non-replication of associations, and may also come up with new 
functional SNPs or markers in LD with functional SNPs for the study area.
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Another great advantage of collaborating with MalariaGEN is that the network 
has access to a large archive of DNA samples from a large number of malaria- 
endemic countries that have ethical approval for genetic studies and this will 
allow me to use a large dataset such as GWAS.
To summarise the discussion above, precedence for the search for host genetic 
factors thought to be important modifiers of SM exists, yet not enough is known 
about which genes are involved or the type or degree of protection that they 
might afford. This thesis seeks to address this question from four main aspects: 
reappraise a range of candidate malaria-protective genes using a large-scale 
case-control study of SM; compare different approaches of detecting epistasis 
interactions and also look for evidence of these interactions between candidate 
genes; examining the haplotype structure and LD for two important variants 
that co-exist in Kilifi and finally to use them in a conditional genome-wide 
association interaction study as a starting point to investigate the process of 
detecting epistasis in SM. To summarise the objectives of the proceeding 
chapters:
1. Chapter 2 discusses material and methods applied throughout the thesis.
2. Chapter 3 reappraise a range of candidate malaria-protective genes using a 
large-scale case-control study of SM.
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3. Chapter 4 compares different approaches of detecting epistasis interactions, 
and also examines evidence of these interactions between candidate genes.
4. Chapter 5 explores the complex haplotype structure and LD patterns for two 
important variants which are found to co-exist in Kilifi.
5. Chapter 6 elucidates a methodological framework for detecting epistatic 
interaction using a genome-wide case-control study
6. Finally, in Chapter 7 general conclusions are drawn and future work that 
may follow this thesis work are summarised.
In the appendices, some additional materials including pseudo-codes that might
be of interest to the reader are presented.
1.6 Motivation for this work
Chapter 2
M aterials and M ethods
2.1 The study area and study site
The study was conducted in Kilifi County on the Indian Ocean coast of Kenya. 
The economy of the area is predominantly rural, being based on subsistence 
farming of maize, cassava, cashew nuts and coconuts as well as dairy cows and 
goats. In addition, two large agricultural estates, two research institutes and 
several tourist hotels contribute to local employment. The majority of the 
population falls within the Chonyi, Giriama and Kauma sub-tribes of the 
Mijikenda ethno-linguistic group.
The County is traditionally a malaria endemic area, transmission being seasonal 
following long and short rainy seasons from April-June and October-November 
respectively. The vast majority of malaria infections in the area are caused by P. 
falciparum. Malaria is predominantly transmitted by mosquitoes of the species 
A. gambiae but A. funestus may also play a minor role [182, 183] with an overall 
EIR estimated at 1-100 infective bites /  year [182, 184]. Over the last two
2.1 The study area and study site
decades, significant declines have been observed both in malaria transmission 
and in the incidence of SM [185, 186]. The present study was conducted at the 
KEMRI /  Wellcome Trust Research Programme (KWTRP) in Kilifi which is 
based in the grounds of the Kilifi County Hospital (KCH), the first referral 
centre for the majority of the population of Kilifi County. The KW TRP was 
established in 1989 and its research interests centre around important child 
health issues [187].
2.1.1 T he Kilifi health and dem ographic surveillance system  
(K H DSS)
The KHDSS was established in September 2000, with the primary aim of 
providing an enabling infrastructure for the conduct of multiple, large scale, 
interdisciplinary epidemiological studies. Many but not all of our studies involve 
an element of case-ascertainment at the KCH. For this reason, the geographic 
limits of the KHDSS are based on the pattern of admissions from the community 
surrounding KCH. Approximately 80% of patients admitted to KCH reside in 
the study area (Figure 2.1 right panel). The KCH admits between 4000 and 5000 
paediatric patients and 3-4000 adult patients each year [187]. The KHDSS is a 
member of the International Network for the Demographic Evaluation of 
Populations and Their Health (INDEPTH) [188], which is a network of 
demographic research centres within the developing world [188].
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The KHDSS covers an area of 891km2 which is divided into 15 administrative 
locations, 40 sub-locations and 186 enumeration zones. The current population 
of the KHDSS area is approximately 280,000 [187]. Every three months the data 
are updated with births, deaths, pregnancies and migration events through 
household visits by enumerators. A critical feature of the KHDSS, that facilitates 
many of the KWTRP objectives, is that all children who present to the wards 
and clinics at KCH are identified in real-time on a central computer-based 
database using a unique personal identification number (PID). This feature 
facilitates research conducted by specific studies within the KWTRP since 
individuals may be traced through all databases and basic demographic 
characteristics such as sex, age, and location of residence can easily be retrieved 
including results of a range of routine laboratory investigations. For instance 
linkages between the KHDSS and the paediatric ward have allowed the KW TRP 
researchers to evaluate the impact of insecticide-treated bed-nets on malaria 
morbidity and mortality in the community surrounding the study area [189].
The KHDSS registers 1200 to 1500 deaths within the resident population every 
year. More than 60% of these deaths occur outside the hospital where the causes 
of death are rarely recorded. In collaboration with the Kenyan Ministry of 
Health (MOH) [190] in 2008, the KHDSS began collecting verbal post-mortems 
of all the deaths reported by field workers with the aim of documenting the
2.1 The study area and study site
pattern of underlying cause of death (COD) at community level using a verbal 
autopsy (VA) tool [191]. The pattern of deaths within the KHDSS, attributed 
according to VA diagnoses, is summarized in Figure 2.2. Of particular interest, 
malaria was the main COD in children aged 1-4 years, despite the reported 
decline in malaria admissions in previous studies conducted in Kilifi [192, 193].
2.1 The study area and study site
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2.2. The study design
In the present study I have utilised two major classes of genetic association 
study designs -  candidate gene and genome-wide -  with an emphasis on how 
each has contributed to our understanding of the genetics of SM in Kenya. Both 
studies were conducted as collaboration between the KWTRP and the 
MalariaGEN consortium.
2.2.1 A  candidate gene case-control study
As the first step to elucidate the pathology of complex diseases such as malaria, 
a study of candidate genes provides various clues to understand genes 
responsible for the phenotype of interest. As shown in Figure 2.3, the general 
workflow of the current study was divided into five steps:
1. Study population
2. DNA extraction and archiving
3. Genotyping
4. Quality control
5. Statistical test analysis
They are all described in the subsequent sections.
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2.2.1.1 Study population
SM cases were recruited as part of on-going surveillance studies of SM at KCH. 
Cases were children aged 0-13 years who were admitted to the high dependency 
unit (HDU) at KCH between June 1995 and June 2008 with P. falciparum 
parasitaemia and one or more clinical features of SM, as described in detail in 
Chapter 1 (section 1.1.3.1). All cases were treated according to standard 
guidelines [195]. For the definition of SM sub-phenotypes, in addition to the 
presence of P. falciparum malaria parasites in the peripheral blood, detected by 
microscopy, I defined CM as a Blantyre Coma Score of <2, SMA as a 
haemoglobin concentration of <5g/dl or a packed cell volume of <15%, and RD 
as the presence of abnormally deep breathing. A number of children had 
combinations of these phenotypes. A subset of children admitted with severe P. 
falciparum infection did not present with CM, SMA or RD but suffered from 
hypoglycaemia, prostration or metabolic acidosis. They were therefore classified 
as a separate category and described as "Other SM". For the purpose of this 
thesis only SMA, CM and RD sub-phenotypes were analysed.
Controls were children 3-12 months of age who were born between August 2006 
and September 2010 within the same study area as cases, and who were recruits 
to an ongoing cohort study investigating genetic susceptibility to a range of 
childhood diseases [196].
2.2. The study design
2.2.1.2 DNA extraction and archiving
Blood samples were collected on admission to KCH for the SM cases while for 
the healthy controls, blood samples were collected during home visits by the 
fieldworkers. Extraction of genomic DNA was done using standard methods; 
either from fresh whole blood samples or from blood samples previously stored 
at -80°C using proprietary methods ABI PRISM (Applied Biosystems, 
California, USA) or Qiagen DNA Blood Mini Kit™ (Qiagen, West Sussex, 
United Kingdom). Aliquots of the extracted DNA samples were sent to the 
MalariaGEN Resource Centre in Professor Kwiatkowski’s Laboratory at the 
Wellcome Trust Centre for Human Genetics (WTCHG), Oxford, UK and 
archived. The archiving process entailed re-labelling of samples with new sample 
identity numbers (ID’s) for confidentiality, determining the concentration of 
samples using the PicoGreen® double strand (dsDNA) DNA Quantification Kit 
(Molecular Probes, Inc) and then placing samples in boxes before storage at - 
80°C. Finally, all the Meta-data regarding the samples was stored into a secure 
web-based laboratory information management system (LIMS) known as 
‘Topheno’ established by the MalariaGEN. Topheno captured essential clinical 
information for individuals in the study (but not personal data) and allowed for 
the conversion of variables to standard units (for example gender coded as male 
or female and parasitaemias converted to parasites per microlitre).
2.2. The study design
2.2.1.3 Genotyping
In order to increase the amount of DNA required for high-throughput 
genotyping, all DNA samples underwent whole genome amplification through 
either Primer Extension Pre-amplification (PEP) Polymerase Chain reaction 
(PCR) using 15N base primers [197] or Multiple Displacement Amplification 
(MDA) [198], before genotyping on the Sequenom® MassARRAY iPLEX™ 
platform (Agena Biosciences, Hamburg, Germany) [117, 199]. More details on 
the genotyping protocol have been described in detail in [45].
In the current study a total of 136 SNPs in 71 malaria candidate genes 
including a+thalassaemia were genotyped. These SNPs were chosen based on 
previously published reports of malaria candidate-gene associations in addition 
to SNPs that had potential associations in GWAS studies undertaken by the 
MalariaGEN consortium [73, 200]. Additional assays were designed for gender 
determination by comparing the Amelogenin gene between the X and Y 
chromosomes (see attributions). DNA samples were also typed for 
a +thalassaemia (the common African 3.7-kb a-globin deletion) in Kilifi and at 
WTCHG (see attributions) by a modified multiplex PCR method as described 
previously [41]. See Table 2.1 for details of the genes/SNPs included in this 
study.
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Table 2.1. The candidate genes selected for genotyping in the case-control
study.
# Gene
sym bol
Gene
description
SN P
name
C h r P osition
1 A J A P 1 Adherens Junctions Associated Protein 1 kgpl5825649 1 48176G4
rs6674631 1 4834821
2 L P H N 2 Latrophilin 2 is146428334 1 81688714
rs72933304 1 81726138
rs72933310 1 81727427
is72933350 1 81751439
is4650365 1 81770827
3 G B P 7 Guanylate Binding Protein 7 rsl803632 1 89582690
4 D A R C Duffy Antigen Receptor for Chemokines is2814778 1 159174683
5 A T P 2 B 4 Atpase, Ca (2+) Transporting, Plasma rs55868763 1 203652140
Membrane 4 isl541255 1 203652141
rsl0900585 1 203654024
is4951074 1 203660781
rs3753036 1 203677250
6 I L 1 0 Interleukin 10 is3024500 1 206940831
isl80089G 1 206946897
rsl800890 1 206949365
7 C R 1 Complement Receptor 1 rsl7047GG0 1 207782856
rsl7047661 1 207782889
8 L O C 7 2 7 9 8 2 - isl371478 2 4901589
is1371474 2 4909777
isl0188961 2 4926593
9 L A P T M 4 A Lysosomal Protein Transmembrane 4 Alpha rs973128 2 20332487
10 S D C 1 Syndecan 1 is l1899121 2 20367973
11 I L I A Interleukin 1. Alpha rsl7561 2 113537223
12 I L 1 B Interleukin 1. Beta isll43634 2 113590390
13 Z S W I M 2 Zinc Finger, SWIM-type containing 2 rs4316902 2 188007364
isl44778284 2 188012821
14 I L 1 7 R E Interleukin 17 Receptor E rs7085G7 3 9960070
15 O X N A D 1 Oxidoreductase NAD-Binding Domain kgp9483807 3 16407519
Containing 1 is79691057 3 16408251
is75180423 3 16408723
1G T L R 9 Toll-Like Receptor 9 isl87084 3 52261031
17 I L 1 7 R D Interleukin 17 Receptor D is6780995 3 57138419
18 A R L 1 4 ADP-Ribosylation Factor-Like 14 is76033371 3 160362359
is75731597 3 160364808
is74954675 3 160381509
19 B 3 G A L N T 1 Beta-1,3-N-Acetylgalactosaminyltransferase 1 rsl2107243 3 160793678
(Globoside Blood Group)
20 T L R 1 Toll-Like Receptor 1 rs4833095 4 38799710
21 T L R 6 Toll-Like Receptor 6 is5743810 4 38830350
rs5743809 4 38830514
22 I N P P 4 B Inositol Polyphosphate-4-Phosphatase, Type II rs77389579 4 143538511
rsl3103597 4 143558581
23 U S P 3 8 Ubiquitin Specific Peptidase 38 1S4266246 4 143971242
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rs28459062 4 144039139
24 G A B 1 GItB2-Associated Binding Protein 1 rs7663712 4 144261117
25 G U S B P 5 Glucuronidase, Beta Pseudogene 5 rsl48111931 4 144540045
26 F R E M S FRAS1 Related Extracellular Matrix 3 rsl84908374 4 144665753
rsl49914432 4 144666678
rsl86790584 4 144680140
rsl84895969 4 144698528
is186873296 4 144702474
27 G Y P B Glycophorin B (MNS Blood Group) rsl91338817 4 144948956
28 C 6 Complement Component 6 rsl801033 5 41199959
29 I R F 1 Interferon Regulatory Factor 1 rs2706384 5 131826880
30 I L 1 S Interleukin 13 rs20541 5 131995964
31 I L 4 Interleukin 4 rs2243250 5 132009154
32 G A B B R 1 Amma-Aminobutyric Acid (GABA) B Receptor,
i
isl92151845 6 29588309
33 H C G 4
1
HLA Complex Group 4 is l14980857 6 29772098
34 L T A Lymphotoxin Alpha rs2239704 6 31540141
rs909253 6 31540313
35 T N F Tumour Necrosis Factor rs1799964 6 31542308
isl800629 6 31543031
is361525 6 31543101
rs3093662 6 31544189
36 H S P A 1 B Heat Shock 70kda Protein IB rs6457452 6 31795550
37 S N O R D 4 8 Small Nucleolar RNA, C/D Box 48 isll6288147 6 31803074
38 C T L 4 - is2242665 6 31839309
39 I L 2 0 R A Interleukin 20 Receptor, Alpha rsl555498 6 137325847
40 P L E K H G 1 Pleckstrin Homology Domain Containing, is55958968 6 150942218
Family G Member 1 rs144224092 6 150973623
rs79100774 6 150975934
rs l14726617 6 150980481
is2131263 6 150981102
rs76924464 6 150982529
rsl51293197 6 150994429
rsl42712208 6 151026346
rsl5116938 6 151046029
rsl4155519 6 151048708
41 N O D I Nucleotide-binding Oligomerization Domain is2075820 7 30492237
containing 1
42 C D 3 6 Cluster Of Differentiation 36 1S3211938 7 80300449
43 T L R 4 Toll-Like Receptor 4 is4986790 9 120475302
rs4986791 9 120475602
44 A B O ABO Blood Group isl50311214 9 136131057
rs56390333 9 136131064
rs8176746 9 136131322
rs8176719 9 136132909
45 M K I 6 7 Marker of proliferation Ki-67 isll016116 10 129975450
rsl48494166 10 129976030
is l15947774 10 130072795
46 R H O G Ras Homolog family member G rs138826089 11 3847190
47 R R M 1 Ribonucleotide Reductase Ml kgpl2768002 11 4111415
48 H B B Hemoglobin Beta Chain rs334 11 5248232
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49 T R I M S Tripartite Motif Containing 5 rs7935564 11 5718517
50 R T N 3 Reticulon 3 rs542998 11 63487386
51 G R I P 1 Glutamate Receptor Interacting Protein 1 rsl92909543 12 67366471
rsl394263 12 67366537
52 C A N D 1 Cullin-Associated and Neddylation-Dissociated 1 rs1566830 12 67369898
rsl2307123 12 67394950
rs10459266 12 67455888
53 I L 2 2 Interleukin 22 rs2227507 12 68642647
rsl012356 12 68644618
rs2227491 12 68646521
rs2227485 12 68647713
rs2227478 12 68648622
54 T P T E 2 Transmembrane Phosphoinositide 3- rsl82873742 13 20050239
Phosphatase and Tensin Homolog 2
55 S P T B Spectrin, Beta, Erythrocytic rs229587 14 65263300
56 L T B P 2 Latent Transforming Growth Factor Beta rs74063230 14 75066093
Binding Protein 2
57 Y L P M 1 YLP Motif Containing 1 rsl0139016 14 75274288
58 R P S 6 K L 1 Ribosomal Protein S6 Kinase-Like 1 rs3742785 14 75373034
59 A D C Y 9 Adenylate Cyclase 9 rs2230739 16 4033436
rsl0775349 16 4079823
60 H B A Hemoglobin, Alpha a+thalassaemia 16 222846
61 I L 4 R Interleukin 4 Receptor rsl805015 16 27374180
62 A D O R A 2 B Adenosine A2b Receptor rs2535611 17 15861332
63 N O S 2 Nitric Oxide Synthase 2A (Inducible, rs2297518 17 26096597
Hepatocytes) rsl800482 17 26128509
rs9282799 17 26128728
rs8078340 17 26129212
64 B C A S 3 Breast Carcinoma Amplified Sequence 3 rsl84142841 17 58855323
65 T B X 2 T-Box 2 rs73991577 17 59323072
66 E M R 1 Egf-Like Module Containing, Mucin-Like, rs373533 19 6919624
Hormone Receptor-Like 1 rs461645 19 6919753
67 I C A M Intercellular Adhesion Molecule 1 rs5498 19 10395683
68 G N A S Guanine Nucleotide Binding Protein, Alpha rs8386 20 57485812
69 D E R L 3 Derlin 3 rs l128127 22 24179132
70 C D 4 0 L G CD40 Ligand (TNF Superfamily, Member 5) rs3092945 X 135729609
rsll26535 X 135730555
71 G 6 P D Glucose-6-Phosphate Dehydrogenase is1050829 X 153763492
IS1050828 X 153764217
All SNPs are referenced to GRCh37, dbSNP135 and Ensemble Build 68. Abbreviations: SNP=Single 
nucleotide polymorphism; Chi—Chromosome.
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2.3.23 Quality control process
The genotype data obtained from the assays are raw data, containing various 
errors due to sample quality or procedural issues. These errors may lead to 
spurious findings; thus a set of quality control (QC) procedures are required. A 
stringent QC process was used to inform the selection of appropriate SNP and 
sample inclusion criteria.
1. Obtaining sample pass rate (the proportion of samples for which the 
genotypes of the SNP were successfully determined) and assay pass rate (the 
proportion of SNPs that were successfully genotyped) for each SNP. The two 
were assessed using the empirical cumulative distribution function and an ad 
hoc cut-off that sensibly removed outlying SNPs or samples was deployed. All 
samples or SNPs with missingness (the presence of undefined genotypes) 
>10% were excluded.
2. An allele frequency threshold of 5% was applied to each SNP. All SNPs with 
frequencies of <5% were removed because of a low statistical power.
3. One method to assess genotyping quality included testing the conformation 
of the observed genotype distributions in the controls to the expected 
distributions under Hardy-Weinberg equilibrium (HWE) using a C7zi-square 
(X2) statistical test, with one degree of freedom. The HWE principle states 
that in a population large enough and in the absence of selection, migration,
2.2. The study design
67
and mutation, the frequency of alleles and genotypes will remain constant 
from ancient generations to current generations. In the HWE model, I 
considered, a single locus with two alleles, noted as ‘A’ (the reference allele) 
and ‘B’ (the derived allele) with allelic frequencies p and q respectively, and 
the frequency (A) = p and the frequency (B) =  q where p-\-q = 1 denotes the 
frequency of the single locus with two alleles. The Equation p2+2pq+q2=l 
describes the frequency of the three possible genotypes of the locus. Then, 
taking into account that the alleles of the controls in the dataset were in 
HWE, the frequency (AA) = p2 for the homozygous wild type in the 
population, the frequency (BB) = q2 for the homozygous carriers, and 
frequency (AB) = 2pq for the heterozygotes. A strong selective force on a 
genetic locus, such as the pressure of malaria, can distort the expected 
distributions under HWE, thus, in the attempt to discriminate between poor 
genotype call rate and selection due to malaria, assays were excluded if the 
HWE probability exceeded the 0.1% significance threshold (P<0.001) rather 
than the commonly used 5% (P<0.05) threshold in the control group.
4. Gender curation was achieved by “genotyping” three fixed nucleotide 
differences between the two copies of the amelogenin gene found on the X 
and Y chromosomes, where male samples were expected to be heterozygote 
for the alleles, and females are expected to be monomorphic. This process
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allowed the curation of clinical gender (the reported gender) obtained 
through the KHDSS and the genetic gender inferred from the typed sample 
from the amelogenin variants.
All of these QC measures were undertaken to retain high quality, high 
information content data but came at the expense of decreased sample size and 
SNP coverage. Finally, prior to analysis, genotype data were recoded based on 
the human genome reference, any remaining heterozygous genotypes found in 
males for the X-chromosome SNPs were coded as missing, and samples for which 
gender or phenotype (case-control status) were undefined were removed.
2.2.2 T h e  G enom e-w ide assoc iation  s tu d y  (G W A S)
The use of a large-scale dataset such as GWAS is undoubtedly of great 
advantage as the genetic basis of resistance to malaria is expected to be around 
many different malaria genes, individually contributing to a small population 
effect, which might be missed due to methodological issues such as sample size. 
We contributed human DNA samples and clinical data from 1,500 children who 
had been admitted for SM as defined in section 2.2.1 along with healthy 
controls, from the candidate gene case-control study discussed above to the 
MalariaGEN consortium for inclusion in a GWAS. I shall refer to this as the 
‘Kenya GWAS data’. Details about these data can be found in the original
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study [158] where the primary aim of the experiment was to identify and 
investigate genetic loci that correlate with SM, and to investigate changes to 
standard methodology (including QC, imputation and association techniques) 
that are required to study data from African population.
2.2.2.1 Genotyping
Samples meeting DNA concentration and genotyping criteria (as described in 
section 2.2.1.3) with appropriate clinical data were selected for GWAS. All 
samples passing initial QC measures (as described in section 2.2.1.3) were sent to 
the Wellcome Trust Sanger Institute in Cambridge, UK for genotyping. Pre- 
genotyping QC was undertaken to confirm DNA concentration, genetic gender 
plus a set of 30 SNPs were generated on Sequenom® MassARRAY iPLEX™ 
platform to serve as a simple check on ‘genotype ability’ for the samples and to 
generate a set of ‘barcode’ markers Samples passing the previous steps were 
genotyped using the Illumina HumanOmni2.5-4 genotyping chip.
2.2.2.2 Quality control
A variety of QC steps were undertaken on the raw data as detailed in Table 2.2. 
A SNP calling threshold of >95% was applied to each SNP. Raw intensities were 
processed via software callers using different algorithms to assess cluster plots of 
signal intensities for each SNP. Consensus calls were made across the callers. 
SNPs less than the calling threshold were further removed.
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SNP were further filtered based on minor allele frequency, and HWE P value. A 
minor allele threshold of >1% was applied to each SNP. An allele whose 
frequency was lower than the threshold was removed. A y? value of lower than 
10'4 was considered a strong evidence of deviation from HWE.
All samples with missingness >2.5% were excluded. Differential missingness 
between cases and controls was also examined, and related samples were 
removed by computing a pair-wise concordance between samples using a 
thinned set of approximately 178,775 SNPs chosen to be at least 0.005cM apart. 
Duplicated samples were also excluded. Ethnicity and gender information were 
compared with the genetic information for consistency and any population 
substructures detected in the data were removed.
2.2.2.3 Imputation
Even though a SNP passed the calling threshold, there were some samples for 
which the genotypes of this SNP were not successfully determined. In such a 
situation, the genotype data was phased using SHAPEITv2.rs644 [201], 
specifying 200 hidden states and an effective population of 17,469 as per 
recommendation for African populations in the software’s documentation. 
Phased genotypes were imputed using IMPUTE v2.3.0 [202] an imputation tool.
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Table 2.2. Quality control for the GWAS.
S N P  filtering  
E xcluded  S N P s w ith :
1. Genotype missing rates >0.05
2. Hardy-Weinberg P values <1x10"*
3. Minor allele frequencies <0.01
Sam ple filtering  
E xcluded  sam ples:
1. Missing genotype rat.e>0.025
2. One sample from each pair of related samples
3. Population outliers detected using Principal Component Analysis
4. Samples with inconsistencies between reported gender and genotype-determined gender
5. Outliers for heterozygosity
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2.3 Statistical analysis
To answer the thesis research questions, different statistical approaches were 
applied on separate datasets discussed in section 2.2. These were: (1) Single 
marker association analysis, (2) Haplotype structure and LD patterns, and (3) 
Multilocus effect (SNP-SNP interactions).
2.3.1 Single marker association analysis
In the candidate gene case-control association study, logistic regression models 
were used to test for associations, and estimate odds ratios and confidence 
intervals. Logistic regression is an adaptation of linear regression in which a 
logarithmic transformation “logit” is used to allow the analysis of a binary 
phenotype (i.e. a case or control). In this approach I modelled the SNP of 
interest assuming several related genetic models (additive, dominant, recessive 
and heterozygous advantage models) and reported the minimum p-values derived 
from these correlated models.
1. The “additive model”: I assumed that the three genotypes of any given SNP 
had an independent effect. In other words, a model of dominance in which 
the heterozygote was at an immediate risk between the two homozygotes.
2. The “dominance model”: individuals with a single copy of a disease 
susceptibility allele were at the same risk of contracting the disease as those
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with two copies (i.e the presence of one copy of an allele increased or 
decreased the disease manifestation).
3. The “recessive model”: individuals with only one copy of the susceptibility 
allele were at the same risk as those with none.
4. The “heterozygote model”: individuals, who carry two different alleles, were 
compared to the other individuals.
Further explanations about the genotypic models of inheritance are summarised 
in Table 2.3.
First I fitted a logistic regression model as shown in E q u a tio n  2.1 to predict 
disease association from each SNP individually. In the model I coded the SNP 
by two indicator variables:
a) One for the heterozygous carrier of the derived allele (Xi) and
b) One for the homozygous carrier of the derived allele (X2)
In other words, I converted AA into “Xi=0, X2=0”, AB into “X i= l, X2=0”, 
and BB into “X i= l, X2= l ” where ‘A’ stands for the reference allele and CB’ 
stands for the derived allele. The case-control status response variable Y was 
coded as 1 for cases and 0 for controls.
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P ( Y  =  1 \ X ,  X 2)
109 \ - P ( Y  = 1 y n ' = & + +  & X21 r ^ i  -L|^l,^2>) (Equation 2.1)
Secondly, I hypothesized that the SNP was not associated with the response 
variable for the null hypothesis (Ho), namely |3i and [32 were zero meaning that 
for the alternative hypothesis (Hi) either (3i or (32 were non-zero.
To measure the genetic effect, the standard odds ratio (ORs), defined as the 
odds of exposure among the cases divided by the odds of exposure among the 
controls, was used. With genotypes coded with respect to the alternate allele, 
and the phenotype coded with respect to the disease status then; an OR of 1 
implied that exposed individuals are at no increased risk compared with those 
who are not exposed, and that an OR of >1 implied an increased risk (or 
positive association), while an OR <1 implied a protective effect (or negative 
association). Odds ratio were estimated by exponentiating the b e ta  coefficients 
of the  model. The above analysis was performed in all SM cases and within 
sub-clinical phenotypes of SM: CM, SMA, and RD.
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T ab le  2.3. Coding of alleles for logistic regression analysis with respect to 
different models of inheritance.
M ODEL A ncestral H eterozygotes  
H om ozygotes
D erived
H om ozygotes
A utosom al chrom osom es and fem ale X chrom osom es
G E N O T Y PE A A  A B B B
A dditive 0 1 2
D om inant 0 1 1
R ecessive 0 0 1
H eterozygote 0 1 0
M ale X  chrom osom es
G E N O T Y PE A B
A dditive 0 2
D om inant 0 1
R ecessive 0 1
H eterozygote n.a. n.a.
In the additive models ancestral-allele homozygotes were coded as 0 for both chromosomes 
autosomes and sex chromosomes, heterozygotes were coded as 1 and derived allele 
homozygotes were coded as 2 (including the male derived-allele homozygotes so that they are 
treated equivalent to the female X chromosome derived-allele homozygotes in the analysis). 
For all other models, the genotypes were coded as 0 or 1 depending on the model grouping 
requirements having 1 with respect to the model and derived allele. n .a.=  not applicable.
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2.3.1.1 Variance explained analysis
Estimation of the proportion of genetic variance explained by host genetic 
factors plays a significant role in understanding a complex trait. Often, the 
coefficient of determination (R2) is used to account for this proportion. In my 
analysis, before calculating the R2, I examined the LD patterns between the 
markers using standardized summary statistic r2 [203]. Due to high LD in some 
of the SNPs within a gene, I only selected the most significant SNP for 
estimating the genetic variance where more than one SNP was typed within any 
single gene.
The proportion of variance explained by a single gene was estimated by 
including one SNP within each gene in a regression model with all covariates 
used in the single-SNP association analysis and, subsequently calculated the R2 
for the full model. I then subtracted the variance explained by a basic model in 
which only covariates were included from the variance obtained from the full 
model.
2.3.2 M ultilocus effects (S N P -SN P  interactions)
One disadvantage of considering only a single SNP effect is that it potentially 
neglects the joint effect of multiple SNPs, where some variants may have little 
marginal effect, but the effect of the variant is more evident when it is altered or
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highlighted by another variant or variants. Therefore, a superior approach to the 
above single-SNP association analysis is the multilocus effect test which 
examines the association of a phenotype with multiple SNPs simultaneously.
In order to detect two-locus epistatic interactions in my data set, three 
representative algorithms were used: P L IN K  (see section 2.3.2.1) and ant-colony 
optimization algorithm (A ntE piSeeker; see section 2.3.2.2), along with my own 
novel method known as ‘Single Nucleotide Polymorphism epistasis’ 
(SN Pepistasis; see section 2.3.2.3). The three computational methods were 
selected because of the clear-cut advantages given in detail in A p p en d ix  A .l  
Table A .I. Table 2.4 further shows similarities and differences among the three 
methods.
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2.3.11 PLINK
2.3.2.1.1 Introduction
PLINK is an open-source C + +  single-threaded, command line program, 
described in detail elsewhere [204, 205]. It has been developed by Shuan Purcell 
at the Centre for Human Genetic Research (CHGR), Massachusetts General 
Hospital (MGH) and the Broad Institute of MIT and Harvard, with the support 
of others [205]. The main purpose of PLINK is manipulating and analysing of 
large whole-genome datasets in their entirety. Its initial functionality covers five 
main domains: data management, summary statistics, population stratification, 
association analysis and identity-by-descent. It has a set of tools for analysis of 
the association of the complete genome. It was designed to perform a range of 
basic, large-scale analyses in a computationally efficient manner. In addition to 
its other functions, it can be used to investigate statistical epistasis.
Currently, PLINK provides both exhaustive and non-exhaustive search methods 
for detecting epistasis. The search for association of 2 loci with a phenotype is 
performed by a module called “epistasis”. PLINK applies a logistic regression 
test for the evaluation of a locus x locus applied according to E q u a tio n  2.2. In 
E q u a tio n  2.2, p is the probability of having the disease, (30 represents the null 
effect, pi and p2 represent the main effects of each locus on the phenotype, and
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p3 represents the interaction term. The variables xi and xg contain information 
about the genotype in both loci and can be encoded in different ways depending 
on the genetic model of inheritance (see Table 2.3). The interaction term is 
encoded by (xi*xs).
Plogit ( P ) =  In-------- =  /?0 +  f i l X l  +  /?2X2 +  J33(xi * X l )  (Equation 2.2)
l - p
The coefficients are estimated for each SNP as well as the interaction between 
them.
2.3.2.1.2 Algorithm
a) For each pair of loci xi and X2, PLINK evaluates the model of interaction 
according to equation 2.2
b) Estimate overall Odds Ratio.
c) Apply the test Z-score (Equation 2.3).
The test Z-score is applied according to Equation 2.3 where the variance V is 
estimated as:
A B C D
rp, ^ _ [0i?(cases -  0 i?(controls)]2
X v S l  2  score
v (cases) + v (controls) (Eqmtion 2 3)
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d) Carry out the control of multiple tests by applying Bonferroni correction (see 
section 2.4.4.1).
23.2.1.3 Parameter settings
Before using PLINK, the raw data were converted to a default file format .ped 
and .map. Typically PLINK requires two or more data files to perform desired 
operation: .ped and .map file in text format. The .ped file is a white-space 
delimited file, containing values of genotypes and information relating to the 
samples. It is made up of six mandatory and two optional columns. The 
mandatory columns contain family ID, individual ID, paternal ID, maternal ID, 
sex and phenotype, respectively. The two additional columns contain names of 
alleles. The .map file, as the name suggest contains the genetic map and has four 
columns: chromosome number, SNP identifier, it's genetic distance (in Morgans 
-  unit for measuring the genetic linkage) and has e-pair position (one kilobase 
equals to 1000 base pairs of DNA). Finally, upon uploading the two standard 
files (.ped and .map) into PLINK, the software performed some extra sanity 
checks on the input data, and later reformatted them to a binary format for its 
own use. The binary file format splits information into three files: the binary .bed 
file (containing genotype information), the text file .fam (storing phenotype 
information) and text file .bim, which is an extended map file (contains two 
extra columns with allele name).
2.3 Statistical analysis
82
To display an epistatic result, the interaction P-value was set larger than the 
default value in PLINK . The analysis was performed using the ‘—epistasis’ 
command for all-SNPs x all-SNPs interactions and the total number of valid 
tests was saved into an output file containing six columns: chromosome of first 
SNP (CHR1), identifier for the first SNP (SNP1), chromosome of second SNP 
(CHR2), identifier for the second SNP (SNP2), ^ s ta tis tic s  (STAT) and an 
interaction p-value (P).
23.2.2 AntEpiSeeker
2.3.2.2.1 Introduction
AntEpiSeeker is an algorithm developed in C++ for detecting epistatic 
interactions in large-scale case-control studies, using an ant-colony optimization 
(ACO) algorithm derived from Dorigo and Gambardella et. al [206]. The use of 
X2 values as score function to measure the association between a SNP set and 
the phenotype has been made computationally efficient.
23.2.2.2 Algorithm
AntEpiSeeker is a two-step algorithm. In the first step, it uses a %2test for an 
association for the interaction between two-pairing loci and the phenotype, and 
initially no assumption about the interaction is made in AntEpiSeeker. In the 
second step, AntEpiSeeker conducts a thorough, exhaustive search of epistatic 
interactions within the set of SNPs that show some evidence of interactions and
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within the reduced set of SNPs with top ranking weights (pheromone levels). 
The use of SNP sets showing some evidence of interaction (much smaller than 
the available SNPs in the data) enhances the power of detecting pure epistasis 
based on greatly reducing the computation time involved and the SNP set with 
top ranking weights is used to detect epistasis among the SNPs with big 
marginal effects. A detailed description about the AntEpiSeeker algorithm can 
be found in [207, 208].
2.3.2.2.3 Parameter settings
Before running AntEpiSeeker, the genotype data file was converted to a comma- 
delimited file, with the first row specifying the SNP names and all subsequent 
rows contained SNP data for each sample. The last column indicated the case- 
control status (0 indicating a control and 1 indicating a case). A separate 
parameter file named "parameters.txt" specified the parameters needed to run 
the program. For my two-locus interaction model the parameters were set as per 
Table 2.4. After running the epistatic interaction, three output files were 
generated "AntEpiSeeker.log" that contained some intermediate results, 
"results_maximized.txt" that contained all detected epistatic interactions, and 
the ‘user-specified output’ file showing the epistatic interactions with minimized 
false positives. The user specified output file included the following columns: the 
locus name, %2 test value and a p-value.
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2.3.2.3 SNPepistasis
2.3.2.3.1 Introduction
SNPepistasis is my proposed novel exhaustive method for detecting two-locus 
epistatic interactions in a case-control study. The algorithm is implemented in 
the R environment which is a free open source statistical software (http://www.r- 
proiect.org).
2.3.2.3.2 Algorithm
I have adopted an exhaustive approach that examines all possible interactions 
among the SNPs. This ensures that I do not miss any statistically significant 
interactions. My method can easily be extended to deal with heuristic search 
approaches. In order to determine significant epistatic interactions for two loci, I 
have used a logistic regression model whereby I have considered two models; a 
model that includes an interaction term (saturated model) and a model that 
omits an interaction term (reduced model) such as the following:
Without . P (Y  — 1) __ (Equation 2.4)
9  P ( Y  =  0 ) =IX  +  1 +  P- 2
interaction:
With P (Y  — 1) (Equation 2.5)
log p ,Y  =  o) =** '+  aX i + 0 * 2  +  r x 1*2
interaction:
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Where the response item at the left hand represents the log odds of the disease 
risk, the right hand represents the independent effect caused by the two SNPs, 
Xi and X2, and the multiplicative term (Xi,X2) represents the epistatic 
interaction. The terms: a , p, y are the size of the effects which are determined in 
the regression analysis and range from 0—1. The epistatic interaction between a 
pair of SNPs and the phenotype was inferred by testing whether the regression 
coefficient y was equal to zero, and this was done by using a likelihood ratio test 
(LRT), which expressed how many times more likely the data are under one 
model (i.e. with interaction term) than the other (i.e. without interaction term).
A P-value as a measurement of the confidence of the epistatic interaction was 
then computed. Considering that the theoretical P value derived from LRT may 
not reflect the true null distribution, I further used permutation test to account 
for multiple comparisons. Finally, an output file “SNPepistasis_output.csv” that 
contained all detected epistatic interactions was generated. The pseudocode for 
SNPespistasis method is shown in A p pend ix  B, S N P ep istasis  p seudocode  
B .l .  Finally, Quantile-Quantile plots (Q-Q plots) were generated using 
customised scripts implemented in R to detect inflation of statistics due to 
population stratification.
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2.3.3 H aplotype structure and LD patterns
Haplotype-based methods utilising SNPs offer a more powerful approach to 
complex disease gene mapping, because they capture the association between 
causal mutations and the ancestral haplotypes on which they arose. For the 
current study, the haplotype patterns across the HbS and a +thalassaemia loci 
were constructed and pairwise LD estimated for the surrounding SNPs in each 
gene using standardized summary statistics [203] D' and r2. These calculations 
were performed using customised R scripts as described in Chapter 5.
2.3.4 M ultiple testing  corrections
Multiple testing is the major concern for the SNP-by-SNP search algorithm. 
Without proper adjustment, it is likely that false positive conclusions will arise 
(i.e. Type I error). The frequentist method for controlling for false positive 
associations is by controlling the significance level, a. The usual choice of a  is
0.05, which implies that the probability of being false positive in all the tests 
carried out is less than 5%. Here I highlight two commonly used approaches for 
adjusting for the multiple-testing problem though various other methods have 
been proposed for controlling issues derived from multiple testing in association 
studies.
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2.3.4.1 Bonferroni correction
Bonferroni correction is often used to control for Type I errors. If n SNPs are 
tested for association, the Bonferroni corrected for each test at significance level, 
a is aJn. For genotype data, the value of “n” can be substantially large and 
depends on the SNP chip used in GWAS studies (e.g. in my data the chip has 
2.5 million SNPs). Bonferroni does not account for correlations between SNPs 
(LD) and therefore can be overly conservative particularly in areas of high LD.
2.3.4.2 Permutation testing approach
Permutation testing is a simulation based resampling method, which controls the 
issues of multiple testing by comparing observed p-values with p-values 
estimated by repeated perturbation of the data and evaluating how often the 
observed p-value can be obtained by chance [209]. In this study, I used the 
permutation approach to select significance levels for further analyses. I 
randomly generated 1,000 permutations of phenotypes across the subjects and 
repeated the analysis in order to find the maximum test value of each 
permutated phenotype and reported these maximum test values. Further details 
regarding the analytical methods are given in their respective chapters.
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2.4 Ethical considerations
Approval for the recruitment of participants, collection of blood samples, DNA 
preparation, genotyping was provided by the KEMRI/Wellcome Trust Scientific 
Coordinating Committee (SCC) in Kilifi, and by the KEMRI Scientific Steering 
Committee (SSC number=1192) and the KEMRI/National Ethical Review 
Committee (ERC) in Nairobi and informed consent from the parents or 
guardians of each study participants.
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Chapter 3
Association analysis between human candidate 
malaria-protective genes and malaria
Abstract
Host genetic factors are thought to be important modifiers of severe and fatal 
malaria, yet there is still a lack of knowledge about which genes are involved or 
the type or degree of protection that they might afford. With this in mind, I 
have undertaken a case-control study in a rural area on the Coast of Kenya to 
evaluate associations between SM and its sub-phenotypes with candidate malaria 
resistance genes. A total of 2245 SM cases and 3949 controls from Kilifi 
populations were typed for a total of 136 SNPs in 71 malarial candidate genes 
using the Sequenom® iPLEX platform and for a +thalassaemia using 
conventional PCR. I found a number of RBC polymorphisms (HBB , HBA , 
G6PD, FREM3 (surrogate for GYP), INPPJ^B, ATP2B4, ABO) being putatively 
associated with differential susceptibility to SM (P<0.005). The total variability 
in the risk of SM that could be explained by all the above malaria candidate
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genes additively was 7.6%. Overall, this study represents the first association 
study from the Kilifi population involving a large number of host genetic factors 
with susceptibility or resistance to SM.
3.1 Introduction
The risk factors for severe disease and the reasons why some children die of the 
disease and not others are poorly understood. Nonetheless, it is known that 
host genetic factors, parasite genetic make-up, host age, state of immunity and 
genetic background play a significant role in determining an individual’s 
susceptibility to many infectious diseases, including malaria.
While a vast body of evidence have been carried out on associations of 
candidate genes with resistance and susceptibility to human malaria [190, 210- 
212], most of these associations have not been conclusively replicated across 
multiple populations. Study design features (e.g. case definitions, sample size, 
study type) and allelic heterogeneity has been proposed as reasons [42]. There 
is a need to unravel host genetic factors tha t provide a significant contribution 
to the variability observed in malaria using a large-scale study which could lead 
to a more unbiased approach to genetic discovery [45, 158].
To begin to explore such contribution in this Chapter, I have utilised a large- 
scale well-characterised case-control study of SM to reappraise 136 published
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SNPs, including loci related to liaemoglobinopatliies, cytokines and other 
immune mediators, thought to be involved in malaria pathogenesis, together 
with their receptors, and promoters, and in addition to SNPs tha t have shown 
early promise for associations in a GWAS undertaken by the MalariaGEN 
consortium [213]. I have further estimated the proportion of the total variation 
explained by these genes in a Kilifi population.
3.1.1 O bjectives
1. Assembling a case-control resource for understanding of protective host 
genetic factors of SM in Kilifi.
2. To reappraise a range of candidate malaria-protective genes in a Kilifi 
population.
3. To estimate the proportion of the total variation in the risk of SM that can 
be explained by these candidate genes.
3.2 Material and m ethods
3.2.1 Study participants
A full description of the study design and study participants is presented in 
Chapter 2 (section 2.1 and 2.2 respectively). Severe malaria cases included 
individuals with CM, SMA, RD or other features of clinical severity who were
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admitted to tlie high dependency ward of KCH between June 1995 and June 
2008 while controls were children born consecutively within the same study area 
as cases who were recruited at 3-12 months of age into the Kilifi Genetic Birth 
Cohort Study between August 2006 and September 2010 as described in Chapter 
2 (section 2.2.1.1).
3.2.2 D N A  extraction and genotyping
Genomic DNA was extracted from samples of blood using methods described in 
Chapter 2 and samples were genotyped using the Sequenom® MassARRAY 
iPLEX™ platform (Agena Biosciences, Hamburg, Germany) for 136 SNPs, and 
PCR was used to detect deletions in the a +thalassaemia gene (see Chapter 2 
(section 2.2.1.2).
3.2.3 Statistical analysis
Single-locus association-analysis adjusted for gender, ethnic group and the HbS 
polymorphism, were performed comparing different phenotypes group of interest: 
a) all severe malaria vs healthy controls; b) all major non-mutually exclusive 
sub-phenotypes: CM, SMA, RD vs healthy controls. Genotypic deviations from 
the HWE were assessed using a %2 statistical test. SNPs were excluded from the 
analysis if there was at least 10% of the genotype calls missing or a significant
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deviation from the HWE (p<0.0001) in controls, or if the overall minor allele 
frequency was less than 0.01 (see Chapter 2, section 2.3.2.3).
Logistic regression models were used to test for associations, and estimate the 
odds ratio and 95% confidence intervals. I modelled the SNP of interest 
assuming several related genotypic models of inheritance (additive, dominant, 
recessive, heterozygous advantage models) and reported the minimum p-value 
from these correlated models. Further explanations about the tests are described 
in Chapter 2 (section 2.3.1).
Statistical analysis of SNPs on the X-chromosome was performed for each gender 
separately. Performing multiple statistical tests leads to inflation of false 
positives. As a result, I used a permutation approach that accounted for the 
correlation between markers and tests, to determine a p-value cut-off for 
statistical significance of 0.005 (Chapter 2, section 2.3.4.2). Further analysis was 
performed to evaluate the proportion of variance explained by a single gene or 
any given locus by including the gene in a regression model with all covariates 
used in the association analysis and calculating the R2 coefficient for the full 
model (Chapter 2, section 2.3.1.1).
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3.3 Results
3.3.1 Overview of study population and exclusion criteria
The process of case ascertainment is summarised in Figure 3.1. In summary, 
there were 62,281 admissions to the KCH paediatric wards during the study 
period (June 1995-June 2008) among which 16,174 (26%) had a positive malaria 
slide and 2245 (3.6%) fulfilled the criteria for SM. The proportion of malaria- 
related admissions relative to admissions due to all causes by year is summarised 
in Figure 3.2.
3.3.1.1 Summary o f Severe malaria cases
The baseline characteristics of the study population are summarised in Table 3.1. 
Of the 2245 cases, 1234 (55%) had CM, 687 (31%) had SMA, 687 (31%) had 
RD, 670 (30%) had CM alone, 230 (10%) had SMA alone, 157 (7%) had RD 
alone, and 436 (20%) with other signs of SM. The male : female ratio was 1.06:
1. The median age of the SM cases was 28 months with an interquartile range 
(IQR) of 15-43 months. The median age of children with CM, SMA and RD was 
28 months, 20 months and 25 months respectively. The SM cases were 
predominantly of Giriama 1326 (59%) and Chonyi 527 (23%) ethnic origin.
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The overlap between SM phenotypes and their case-fatality rates are 
summarised in Figure 3.3. Of 2245 cases, 263 died (56% male), giving an overall 
case fatality rate of 12%. The median age of the cases that died was 28 months 
(IQR: 2-132 months). Children with CM had the highest case fatality rate 
ranging from 11% for CM accompanied with SMA to 23% when CM was 
accompanied by both SMA and RD. RD alone had a case fatality rate of 8%. 
The lowest case fatality rate was observed in children admitted with SMA as the 
only clinical feature 7%.
3.3.1.2 Summary o f healthy controls
A total of 34,714 children were identified between May 2006 and February 2011 
as being eligible for inclusion in the ongoing prospective Kilifi Genetic Birth 
Cohort Study (see Chapter 2 section 2.1.1). 16,275 healthy children aged 3-12 
months were consented and enrolled in this study. Of these, 11,050 (68%) have 
so far been genotyped for various malaria candidate polymorphism and of these, 
3,949 were selected using pseudo-random sampling as potential controls to be 
included in the final case-control analysis (Figure 3.4). The selected controls had 
a median age of 6 months, were well balanced for gender (50% were male) and 
were from predominantly of Giriama 1836 (46%) and Chonyi 1421 (36%) ethnic 
origin (Table 3.1). No significant difference was observed between the cases and 
controls with regard to ethnicity.
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F igure  3.1. Schematic process for the recruitment of cases into the candidate 
gene case-control study.
All admissions to paediatric wards between June 1995 to 
June 2008
62,281
------------------------------------------► Age >13 years or date 
of birth missing
498
Aged 0-13 years 61,783
No blood slide result 
reported
13,407
r
With malaria blood 
slide results
48,376
y
Blood slide negative 32,203
r
Blood slide positive 16,173
1
Missing clinical or 
genotype data
168
No clinical features of 
severe malaria
13,760
Severe malaria 2,245
included in analysis
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F igure 3.4. Selection of healthy controls for the candidate gene case-control study.
Not visited 2,579
Not consented 18,439
Others 7,101
C ontro ls inc luded  in 
analysis
3,949
Consented 16,275
Visited by FWs 34,714
With genotypes 11,050
HDSS births -  May 2006 to Feb 2011 37,293
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3.3.2 A ssay pass rate
Genotype call rates for each multiplex were checked and assays with call rates of 
<95% were excluded from further analyses. A total of 136 assays were 
performed, with 121 assays achieving a pass rate of ^ 95% (Figure 3.5).
3.3.3 Sam ple pass rate
The performance of sample collection across the 136 SNPs was calculated as 
sample pass rate. Samples with call rates of <95% were excluded from further 
analyses. A total of 6,214 samples were assayed, with 6,194 samples achieving a 
pass rate of >: 95% (Figure 3.6).
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F igure  3.5. The performance of 136 assays successfully genotyped in the 
candidate gene study.
0.95-
»0.90-
0 10 20 30 40 50 60 70 80 90 100 110 120 130
Assay rank order pass rate
Assays have been ranked in order of pass rate from high to low (x-axis) and plotted against 
their pass rate (y-axis). A total of 136 assays were performed, with 121 assays achieving a pass 
rate of ^95%.
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F igure 3.6. Performance of the samples included in the candidate gene case- 
control study.
1 . 0 0 -
Q.
CL
£-0.85
0.80-
3000 40001000 2000 50000 6000
Sam ples rank order pass rate
Samples have been ranked in order of pass rate from high to low (x axis) and plotted against 
their pass rate (y axis). A total of 6,217 samples were assayed, with 6,194 samples achieving a 
pass rate of ^95%.
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3.3.4 Single-SN P association analysis
Overall, fifteen SNPs were removed from the analysis because they were 
monomorphic (i?C!A5«2-rsl84142841, (7jRZPi-rsl92909543, GUSBP5-rsl48111931, 
i7RB-rs33950507, #B^rs33930165, ICAM 1-rsl799969, LTBP2- rs74063230,
O XN AD l-kgpM 8m 7, OXNAD 1-ts75180423, OXNADl-rs79691057, PLEKHG1- 
rsl4422409, RHOG-vs138826089), had high rates of missing genotype calls 
(GYP£-rsl91338817, TiVF-rs1800750), or deviated from HWE among controls 
(RPS6KL1-ts3742785) , leaving 121 polymorphic SNPs that could be analysed for 
their association with the four SM groups.
Figure 3.7 shows the minimum p-values from the genotypic tests applied to the 
autosomal SNPs. Twenty one loci including a +thalassaemia were found to be 
highly associated with SM (P^0.005). Interestingly, majority of these 
associations were related to the RBC polymorphisms. The most significant 
association being observed with HBB-rs334 located on chromosome 11 
(P=1.35 xlO'59). The remaining significant loci, ranked by chromosome position 
were: four SNPs in the ATP2B4 gene located on chromosome 1 (rsl0900585, 
P=0.005; rsl541255, P=0.002; rs55868763, P=0.002), one SNP on the IL10 gene 
located on chromosome 1 (rsl800890, P=0.002), three SNPs on the LPHN2 
gene located on chromosome 1 (rs4650365, P=0.004; rs72933304, P=0.002;
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rs72933350, P=0.004), tliree SNPs on the LOC727982 gene located on 
chromosome 2 (rsl371474, P=5.68xl0 '6; rsl371478, P=2.57xl0 'c), three SNPs 
on the ARL14 gene located on chromosome 3 (rs74954675, P =  0.004; 
rs75731597, P=0.001), three SNPs on the FREM3 gene located on chromosome 
4 (rsl49914432, P=6.17xl0 '13; rsl86790584, P=1.98xl0 '13; rsl86873296,
P=3.13xl0 '14), two SNPs on the INNP4B  gene located on chromosome 4 
(rsl3103597, P=7.57xl0 '6; rs77389579, P=5.85xl0-9), two SNPs on the ABO  
gene located on chromosome 9 (rs8176719, P=2.14xl0 '8; rs8176746, P=9.72x10' 
9), one SNPs on the RPS6K L1 gene located on chromosome 14 (rs3742785, 
P=0.001) and one other on the HBA gene located on chromosome 16 
(a+tlialassaemia, P=1.35xl0 '6) (Figure 3.7 and Table 3.2).
Odds ratios for each of the four phenotypes are depicted using Forrest plots in 
Figure 3.8. The greatest magnitude of effect was seen in the HBB and FREM3 
loci (85% and 45% relative reduction in SM, respectively). In contrast to a 
number of previous studies, which have suggested that a +thalassaemia might 
specifically protect against severe malaria anaemia [62, 66, 214], in this analysis 
it was associated with protection from all major phenotypes of SM (Figure 3.8; 
Table 3.2).
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The rsl050828 (G6PD-202, X-chromosome) SNP was weakly associated with a 
decreased risk of SM overall (OR 0.82, 95% Cl 0.70-0.97, P=0.01), but by 
contrast was associated with a paradoxically increased risk of SMA (OR 1.80, 
95% Cl 1.34-2.40, P=0.0001) (Table 3,3). Further interrogation of the data 
revealed that this was explained by the fact that the G6PD-202 deficient 
heterozygous females (OR 0.82, 95% Cl 0.70-0.97, P=0.01) were relatively 
protected against SM, but not the more severely deficient hemizygous males (OR 
1.10, 95% Cl 0.92-01.33, P=0.29). The deficient hemizygous males were found 
to be susceptible to SMA (OR 1.86, 95% Cl 1.36-2.54, P=0.0001) (Figure 3.7, 
Figure 3.8 and Table 3.3).
CDJ^OL-rs3092945, a glycoprotein X-linked gene was found to be associated with 
an increased risk to SM (OR 1.14, 95% Cl 1.06-1.22, P=0.0002) and SMA (OR 
1.35, 95% Cl 1.08-1.68, P=0.009). I observed an association between rs3092945- 
CD40LG-727 and both SM (OR 1.24, Cl: 1.10-1.41; P=0.0006) and CM (OR 
1.97, Cl: 1.31-2.96; P=0.002) for females and a marginal association in males 
with SM as shown in Figure 3.7, Figure 3.8 and Table 3.3. Association analysis 
minimum p-values for mutually-exclusive SM phenotypes (i.e.CM only, SMA 
only and RD only) are presented in A p pend ix  C, F igu re  C .l.
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F igure 3.7. Shows the distribution of minimum p-values from the genotypic 
tests for the severe malaria and its major sub-phenotypes.
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3.4.5. C ontribution of malaria candidate genes
Before, calculating the genetic contribution of the variation in malaria risk it was 
important to examine the LD patterns of different SNPs within the same genes. 
This was done using a standard LD metric measure r2 (Chapter, section 2.3.1.1). 
Figure 3.9 shows the LD pattern among 121 markers that were analysed. 
Inspecting by eye the SNPs within ATP2B4 or the FREM3 gene regions were in 
high LD. For this reason, only one SNP (the most significant) within a gene was 
included in the regression to estimate the variance explained. Figure 3.10 shows 
the proportion of variance explained by all the candidate malaria genes based on 
the R2. The HbS locus contributed to the most of the total genetic variation. 
The total variability in the risk of SM that could be explained by all the above 
malaria candidate genes additively was 7.6%.
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3.4 Discussion
Genetic association studies utilising polymorphic markers in candidate genes 
have been successful in identifying a number of genes that are associated with 
susceptibility to SM. However, it must be acknowledged that the current 
literature contains inconsistencies and conflicting lines of evidence. W ith this in 
mind, I carried out a large case-control study of SM within a single, well 
characterised population, on the coast of Kenya. A major aim of this study was 
to reappraise previously published reports of malaria candidate-gene associations 
and in addition other SNPs that had potential associations in a GWAS 
undertaken by the MalariaGEN consortium [213]. I investigated genetic 
associations with SM in general and with three major sub-phenotypes of SM: 
CM, SMA and RD.
To minimise errors I standardised procedures using pre-defined definitions of SM 
and clinical sub-phenotypes, and ensured all samples underwent genotyping on 
the same Sequenom Mass Array platform with resulting low rates of missing 
data (<5%). In addition, all analyses were adjusted gender, ethnic group and the 
HbS polymorphism.
Based on data from my case-control study, most children presenting with severe 
falciparum malaria were less than 5 years old (88% of 2245 cases). Similar 
observations have been made in another group of children hospitalised for
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malaria in Gabon [215]. Elsewhere, SM tends to occur in older children [216]. 
Differences in the age of presentation of SM may be the result of lower 
background immunity or other undefined factors [217]. Cerebral malaria was the 
most frequent feature of severity. Children with SMA had a lower fatality than 
children with other complications of severe malaria, these results are consistent 
with other studies that used hospital admission data [218, 219]. The overall case 
fatality rate of SM in the study was 12% (263 deaths/2245 cases), which is in 
keeping with other studies, where case fatality rates ranged between 8 and 40% 
[22, 218, 220, 221].
Notwithstanding the ascertainment bias, data from this study showed that 
polymorphisms affecting various aspects of RBCs (including HBB, HBA , G6PD , 
FREM3, INPP4B, ATP2B4 and ABO) were among those associated with the 
strongest signals of differential susceptibility to SM. As expected given previous 
observations of the strong genetic effect of the HbS locus on malaria [46, 222], 
this study, confirms the known (-90%) reduced SM risk from the HbAS 
genotype [73] although the protective effect that I observed was smaller than in 
some previous reports. These differences could be due to the fact that my cases 
were children of young age (mean age 27 months) and thus they lacked immune 
basis for HbAS protection [223]. Nevertheless, despite this rigorous 
epidemiological evidence, the exact mechanism by which HbAS protects against
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malaria is not fully understood. A recent study in Kilifi has shown that the 
protection afforded by HbAS increases with age, an observation consistent with 
enhanced acquisition of natural immunity to malaria due to the accelerated 
acquisition of antibodies against altered host antigens expressed on the surface of 
the infected RBCs [223].
The study further confirmed the known protective effects of the blood group O 
on life threatening malaria, which is thought to act on malaria pathogenesis 
through the mechanism of reduced P. falciparum rosetting [67, 224]. In a case- 
control study conducted in Mali, children with blood group O were found to be 
protected against SM through the mechanism of reduced P. falciparum rosetting 
[67]. Similar observations have been found in Kilifi in Kenyan children with SM 
[224].
The study also confirmed protective effect of a +thalassaemia against severe P. 
falciparum disease. Previous studies have suggested that some of the traditional 
candidates might be associated with specific effects against particular sub­
phenotypes of malaria. In this study however, there was little to  suggest that 
this is true for most of the candidates, including a +thalassaemia which others 
[41, 62, 66], have previously suggested might be particularly protective against 
anaemia. An explanation for this discrepancy probably relates to the sample size 
of these previous studies have been relatively small.
3.4 Discussion
120
Much controversy has surrounded the question of the protective role of G6PD 
deficiency in malaria, and several studies have come up with conflicting results. 
Some studies have observed that individuals who are deficient (male hemizygotes 
and female homozygotes) are protected from malaria [225-227]. However, other 
studies have suggested that only females are protected [228]. This controversy is 
partly due to the fact that this disorder has three common X-linked alleles in 
Africa, which makes analysis and determining the phenotype difficult. In Kilifi, 
my colleagues have already proved that G6PD+202T allele is the only significant 
cause of G6PD [229] making results from this study more robust than a number 
of previous studies that have been undertaken in populations in which G6PD 
deficiency has subsequently been fomid to have a more pleomorphic aetiology. 
This study provides evidence that the G6PD+202T allele provide reduced risk 
for SM and SMA risk in deficient heterozygous females while increase risk to 
SMA in deficient hemizygous males. More recent research by the MalariaGEN 
consortium has found similar results [45]
In addition, to the traditional candidates, in this study, I have confirmed the 
associations of ATP2B4 [230] gene, which is a membrane calcium transport 
protein, FREM3 gene, which is an extracellular matrix protein and may play a 
role in parasite invasion and INPPJ^B, which is a protein binding gene. Both
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FREM3 and INPP4B  are immediate neighbours to the Glycophorin region 
( GYP A , GYPB , GYPE) and more likely markers for that region [213].
Besides the RBC polymorphisms, the evidence supporting other associations, 
mainly in cytokine or cytokine related gene polymorphisms are not far-fetched. 
Over the last few years, a body of literature has emerged that contend that the 
effects of cytokines combine to make falciparum malaria primarily an 
inflammatory cytokines driven disease [231, 232]. An excessive cytokine-mediated 
inflammatory response could result to SM [233]. In this present study, I did not 
find any association of cytokines polymorphisms with SM, given the statistical 
power of my study. To date, the replication of cytokine gene associations with 
SM has proved difficult perhaps because they are not real or because their effect 
sizes are small. Malaria is a highly heterogeneous disease between countries 
dependent on many variables such as geography, mosquitoes, rainfall and the 
immune status of people living in such areas all of which can be difficult to 
accurately quantify and account for. There is also the genetic variation of the 
malaria parasites between regions, although this is becoming a more tractable 
problem with the current genomic studies being undertaken. There is also the 
possibility that regional associations of cytokine polymorphism could be real as 
there are examples for other genes where this occurs, for example, HbC is 
localised to parts of West Africa, HbS to Africa and part of the Indian sub­
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continent and the distribution of the different a+thalassaemia polymorphisms 
between Africa and Southeast Asia. Notwithstanding these factors, sample size 
may be one of the biggest factors and to date many studies have been of modest 
size. The present study is one of the biggest single-site genetic studies of severe 
malaria and for many of the published cytokine associations I did not find any 
supportive evidence for their association.
The most obvious limitation of the study was some children had more than one 
diagnoses on clinical examination, though these numbers were too small to affect 
the conclusion of our study. This problem is also shared by other similar studies 
on SM [218, 234, 235]. Nevertheless, this study provides useful data; to support 
the epidemiological and immunological studies conducted in Kilifi. Ultimately 
the study has also expanded our understanding of predisposing factors of SM in 
Kilifi and important SNPs identified may contribute to the design of future 
studies in the area.
In conclusion, I have conducted a large case-control study using a candidate 
gene approach to evaluate many previous reported associations including SNPs 
investigated from the MalariaGEN GWAS. More interestingly, the top putative 
associations with differential susceptibility to SM were to be linked to the RBC 
polymorphisms (HBB, HBA, G6PD, FREM3 (surrogate for GYP), INPP4B, 
ATP2B4, ABO), indicative of parasite driving RBC changes. Future functional
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studies of this sort should investigate the mechanism of protection afforded by 
these RBC polymorphisms which may provide new insights into the biology of 
SM that could inform the development of new approaches to prevention and 
treatment. Putting the above observations together raises the question of 
whether the above RBC- related polymorphisms are acting independently, or 
whether some of them are interacting to bring about protection. This will be my 
main focus in the next Chapter.
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Chapter 4
Identifying genetic epistasis in a candidate-gene 
case-control study
Abstract
In recent years, a number of computational and statistical difficulties for 
identifying SNP-SNP interactions in high dimensional data have been studied, 
and several data mining approaches have been proposed. However, to the best of 
my knowledge the relative performance of these methods to detect SNP-SNP 
interactions has not been thoroughly investigated using a real data set. In this 
study, I directly compared the performance of three algorithms to detect gene- 
gene interactions in a candidate gene case-control study analysed in Chapter 3. 
Three methods were evaluated for their ability to detect SNP-SNP interactions: 
PLINK, AntEpiSeeker and SNPepistasis. Methods were contrasted on the basis 
of which SNPs they selected including computational cost. The results of this 
study demonstrate how the methods performed in detecting gene-gene 
interactions for a real data set, and it will be interesting to see how they perform 
using a large-scale data such as a GWAS study.
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4.1 Introduction
One of the main primary goals of human genetics is to discover the relationships 
between genotypes and disease status. Although single-locus approaches have 
fruitfully uncovered many genetic determinants of disease susceptibility, such 
approaches cannot adequately explain the genetic contribution to complex 
diseases such as malaria. An alternative explanation is that the effects of 
individual genes in predicting complex phenotypes are not always necessarily 
independent and that epistasis contributes substantially to major human diseases 
[236, 237]. Identifying epistatic SNP interactions is of interest as it may enhance 
our current understanding of disease etiology.
As discussed in Chapters 1 and 2, there are numerous statistical methods and 
computational algorithms that allow investigators to test for interactions 
between loci. It is difficult to recommend the best algorithm without careful 
comparisons because of the huge difference between them, including interaction 
definitions, null distributions [238] and even how they include potential 
confounders. Several attempts have been made to evaluate different methods 
[208, 239-244]; however, there has been little effort to compare the performance 
of the different methods in the presence and absence of interactions using real 
data. Real data are preferable under many circumstances, since contrived models 
may not accurately represent complex biological processes. As it was pointed out
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in the introduction chapter, there are two groups of methods in detecting 
epistasis, classified according to their search strategy: methods based on 
thorough search and methods based on search which is not exhaustive also 
known as stochastic search and/or greedy. In this chapter I have compared the 
performance of a method that I have developed (SNPepistasis, an exhaustive 
method) with two other well-known algorithms; PLINK (which is both 
exhaustive and non-exhaustive) [205], and AntEpiSeeker (which is a non- 
exhaustive) [207] using my case-control dataset.
4.1.2 Objectives
The central aims of this chapter are:
1. To develop a novel method that searches all possible two-locus combinations 
for evidence of epistatic interactions.
2. To compare the results of the novel method with other existing algorithms in 
the literature.
3. To identify whether polymorphisms typically act independently or whether 
their effects are dependent on other polymorphisms in the rural population of 
Kilifi.
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4.2 M ethods
4.2.1 Sample
In this chapter I have used the same severe malaria case-control study 
described in Chapter 2 section 2.1.1 tha t was used for the candidate single­
locus association study described in Chapter 3. Overall, this dataset includes a 
total of 2245 SM cases and 3949 healthy controls with all individuals genotyped 
for 114 autosomal SNPs in 71 candidate malaria genes plus cCthalassaemia 3.7kb 
deletion. While interactions between different X-linked SNPs and between X- 
linked and autosomal SNPs are of potential interest going forwards, their 
inclusion in this exploratory work adds a number of additional challenges 
including issues of power (because analyses would need to be stratified by sex) 
and issues relating to variable rates of Lyonisation in heterozygous females. As a 
consequence, I have restricted my current analyses to autosomal SNPs.
4.2.2 Statistical analysis
Initial screening of all SNPs, testing for HWE (separately in cases and controls), 
genotyping efficiency, and single-locus tests for association were described in 
Chapter 3. All the experiments were conducted on a 64-bit Windows system, 
with Intel ® Core'1’1'1 i7-4980HQ CPU with 2.80 GHz central processing unit host 
(CPU) using 16 GB of memory. To measure the significance of the epistatic 
interaction between pairs of SNPs and SM phenotypes, three computational
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methods were used: PLINK, AntEpiSeeker and SNPepistasis (see Chapter 2 
section 2.3.2 for detail). All analyses were conducted with adjustment for the 
potential confounders ethnic group and gender. The permutation test approach 
was used to control for multiple testing; this estimated a p-value threshold of
0.003. I also recorded the runtimes for each analysis for each of the softwares.
4.2.2.1 Reporting interaction results
Reporting significant epistatic interactions of SNPs involve two major 
challenges. First, since a huge number of possible combinations are tested, a 
large proportion of significant associations might be false positives. In this case, 
I validated my results using Search Tool for the Retrieval of Interacting 
Genes/Proteins (STRING) database h ttp ://string .embl.de/ [245]. This tool has 
two main advantages: (1) It combines the information from many Protein- 
Protein Interaction (PPI) databases and (2) it provides a score for each 
interaction based on the number and quality of the reported interactions 
between the two potentially interacting proteins. How does the tool work? Given 
a PPI network, a set of genes that may be related to this network in some way, 
and an underlying interactome (e.g. parts from a protein-protein interaction 
database), the tool tries to connect the submitted genes to the network, using 
interactions from the PPI databases, and then reduce this extended network to 
only the most biological plausible interactions. In addition, computationally 
predicted interactions are included as these may introduce edges in the network
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interaction-graph, that have not yet been fully experimentally discovered. 
Further detailed description of the tool can be found elsewhere [245]. The second 
major challenge involved interpretation of the results and developing them into 
biologically meaningful hypotheses. For this reason, I selected two pairs of 
genes with multiple lines of evidence that they genuinely interact and 
examined them in greater depth.
4.3 Results
4.3.1 A pplication to  th e  real data
4.3.1.1 Comparison o f computational time
The efficiency of the three computational methods was demonstrated by 
comparing runtimes. The real (clock) time required to complete the epistasis 
analysis were 120, 130 and 132 seconds for AntEpiSeeker, PLINK, and 
SNPepistasis respectively. Not surprisingly, exhaustive methods (PLINK and 
SNPepistasis) took a longer time to enumerate all pairs of loci, though the 
difference with the non-exhaustive search method (AntEpiSeeker) was small.
4.3.1.2 Statistical Performance
The completeness space for the three methods is shown in Figure 4.1. As there 
are three methods, three Venn diagrams are drawn respectively. The two 
methods used x2 test: PLINK and AntEpiSeeker while SNPepistasis used LRT to 
test the interaction between two SNPs. Comparing the three methods,
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AntEpiSeeker identified more pair-wise interactions (6,340), than the other two 
methods; PLINK identified 6,330 pairs while SNPepistasis identified 6,331 pairs.
Figure 4.2 is a Q-Q plot showing that the distribution of interaction term p- 
values deviates from the expected uniform distribution under the null hypothesis 
of no epistasis (red diagonal line) for the three methods. According to the plot, 
the genomic inflation factors were 0.98, 1.04 and 1.02 for PLINK, AntEpiSeeker 
and SNPepistasis respectively, suggesting that confounding factors such as 
population structure have been well accounted for on all interaction analysis. As 
the Figure 4.2 shows, the 3 methods all produce similar plots with a low 
‘inflation’ from the red diagonal line and I therefore assume that results are 
normally distributed and that the right-hand tail of deviation above the diagonal 
red line may harbour significant results.
Figure 4.3 shows a M anhattan plot of the pairwise (SNPs pairs >6000) p-values 
derived by the three computational methods. The plot strongly suggests that 
there are plausible (and interesting) interactions using a threshold of P < 0.003 
(derived from permutation testing). The x-axis does not represent any particular 
feature or order except the SNP pair. All three methods showed similar 
distributions of the P-values for the SNP pairs (A ppend ix  D , F igure  D .l) .
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F igure  4.1. The completeness interaction search space for the three 
computational methods.
A ntE piSeeker-n=6340
PL IN K - n = 6330
SN P epistasis- n = 6331
As there are three methods, three Venn diagrams are drawn respectively. PLINK and 
AntEpiSeeker methods used x  test while SNPepistasis used LRT to test for interactions 
between two SNPs. PLINK identified 6,330 (6,326 +  4) pairs, AntEpiSeeker identified 6,340 
(6,326+4+5+5) pairs, while SNPepistasis identified 6.331 (6,326+5) pairs.
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Figure  4.2. A Q-Q plot comparing the observed -logio-transformed P-values 
from the expected uniform distribution of P-values for the three algorithms.
1.04
0.98
1.02
O)o
TJ<D
&
V)JQ
o
CM
Antepi seeker 
Plink
SNPepistasis
o
20 1 4
Expected - lo g 10(p )
On the x-axis the expected uniform distribution from the %2 test is compared to the observed P- 
values from the interaction analysis derived by the three methods on the y-axis. A red line has 
been added to show the expected relationship between the 2 distributions under a null model of 
‘no-effect’. Deviation from the diagonal red line (typically y =  x) can indicate aspects of data 
quality or some interesting interactions.
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F igure  4.3. Shows a M anhattan plot of the p-values derived by the three 
computational methods for all 114 SNP pairs.
AntEpiS-aa^er PUNK SNPepistasis
0 1 2 3 4 5 0 1 2  3 4 5 0 1 2  3
- lo g 10(Pvalue)
The dashed line represents a p-value threshold of <0.003. The X-axis depicts -log p-value and 
the Y-axis are the SNPs pairs.
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Table 4.1 reports the top 50 SNP-pairs p values (<0.01) detected by each of the 
three ‘interaction’ methods. The Table shows for each SNP pair, their minor 
allele frequencies, their chromosome positions, the direction of epistatic 
interaction (positive or negative), represented by the interaction odds ratio ( I o r ) ,  
and the P-values derived by the interaction. The table further shows that across 
the top 50 signals for each computational method the results are comparable. 
Furthermore the interaction identified the same top most SNP-pair interactions 
between INPPJ^B SNP rsl3103597 located on chromosome 4 and TNF  SNP 
rsl799964 located on chromosome 6 (interaction P<0.00002).
Figure 4.4 shows a graphical visualization of epistatic interactions for the top 50 
hits. This method of visualization is termed as a two-way or solid edge. The 
nodes show the gene names and the connections show the interaction where the 
width of the line is proportional to the strength (Odds ratio) of the interaction. 
The labels in black show the ORs value. A red line signifies a negative epistatic 
interaction (OR >1) and a blue line depicts a positive epistatic interaction (ORs 
<1). For example, from the figure it can be seen that there is negative epistasis 
between the HBB gene and four other malaria candidate genes: HBA, USP38, 
LPHN2 and TNF, and a positive epistatic interaction with the LOC727982 gene.
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F igure 4.4. A two-way epistatic interactions network among the top 50 hits.
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Nodes in green colour are the gene names. Labels in black show the strengths of interaction
effects and the edge width is proportionally adjusted to the ORs value. A red line signifies a 
negative epistatic interaction (OR > 1) and a blue line depicts a positive epistatic interaction 
(ORs <1). The data for PLINK are shown in this figure.
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4.3.2 Biological Interpretation
One of the biggest challenges in examining epistatic interactions between genes 
or SNPs is the interpretation of the results. To begin, I have asked myself three 
basic conceptual questions:
1. W hat do all these statistically significant interactions mean?
2. Are they all real and do I believe them?
3. Which of the many significant gene interactions are useful for predicting who 
is at risk for SM?
There are all basic questions that require critical thinking. Nevertheless, I still 
need to interpret these results in the context of human biology so that they may 
be used for the benefit of disease treatment and prevention. Here, I focused on 
two different approaches. First, as a proof of principle, I selected two pairs of 
variants (HbS and a+thalassaemia) with multiple lines of biological evidence 
that they genuinely interact and examined them in greater depth [57, 62, 103]. 
Returning back to the epistatic interaction results detected by the three 
computational methods (Table 4.3 and Figure 4.4), they all confirmed 
(AntEpiSeeker P=0.02, PLINK, P=0.01 and SNPepistasis P=0.01) some 
evidence of epistatic interactions between HbAS and a+thalassaemia with SM. 
To aid interpret these results, I used a Forrest plot to illustrate the effect of the 
interaction between HbS and a+thalassaemia compared (Figure 4.5).
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F igure  4.5. A Forrest plot for epistasis between HbAS and cdthalassaemia for 
association with SM.
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For each combination of genotypes (x-axis), I com puted the odds ratio  ±95%  C l (y-axis) and 
p-value relative to  the reference group (odthalassaemia: aa /a a /H b A A ). The red line shows the 
point of no effect. The odds ratio has been plotted on a log scale so th a t the distances above and 
below 1 represent the same size of effect although opposite effect. I also list the sample size for 
cases and controls. Three m ethods have been used to  detect this epistasis: AntEpiSeeker 
(P=0.02), PLINK (P=0.01) and SNPepistasis (P=0.01). The da ta  for SNPepistasis are shown in 
this figure. The protection afforded by both polymorphisms when inherited together is reduced.
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Allele group “a” shows the baseline for normal a +thalassaemia and HbAA. As 
shown in allele groups “a”, “b” and “c”, on a normal HbAA background, 
a +thalassaemia tends to protects reaching an OR of 0.6 in the homozygote state. 
However, this trend for protection is not seen in individuals with HbAS, indeed 
the oc+thalassaemia locus reduces the effect of HbAS (OR 0.1 to 0.2).
The second approach was to check if epistatic interactions reported from my 
analysis had evidence from the literature and biological databases. The tool used 
for this was the STRING database. I submitted a list of protein names 
included in my study to the database for construction of a protein interaction 
network as seen in Figure 4.6. Interestingly, the STRING tool demonstrated 
that haemoglobin related proteins: HBA1, HBA2 and HBB for which there was 
evidence of epistatic interaction clustered together and formed an interaction 
network. I further compared the top 50 interactions as reported in Figure 4.4 
with the nodes of the interaction network generated by the STRING program 
(Figure 4.6). From this comparison, 3 interactions gene-pairs from Figure 4.4 
matched interacting nodes from the STRING database. These gene interaction 
pairs were: TNF-IL10, TNF-IL13 and IL10-IL13. Moreover, this seems like a 
higher order (3-way) interaction. The presence of these interactions in STRING 
database appears to validate my results.
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Figure 4.6. Illustrates the protein-protein interaction network generated from 
STRING.
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The graph was generated using STRING. Edges in this graph only mean th a t in some publication
evidence was found th a t the connected genes interact. There is no tem poral or directional component 
given in this graph. Purple lines indicate evidence from experiments, blue lines indicate homology of 
sequences, green lines indicates evidence from text-mining, dark green node indicates association by 
neighbourhood, Red node indicates association by gene fusion whereas a blue node indicates 
association in gene and protein databases. Haemoglobin related proteins: I I B A l ,  H B A 2  and H B B  for 
which there is evidence of epistatic interaction is marked with a red circle.
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4.4 Discussion
It is now widely accepted that multiple genes may be responsible for many 
complex diseases and as such in the study of such diseases, emphasis is now been 
placed on finding all possible epistatic interactions between these genetic 
variants [246, 247]. By allowing for epistatic interactions between potential 
disease loci, we may succeed in identifying genetic variants that might otherwise 
have remained undetected. In addition, the identification and characterization of 
epistatic interactions might provide new knowledge on complex genetic 
mechanisms that underlie complex diseases [248] such as malarial disease.
Methods of analysis that detect or control the phenomenon of epistasis are 
clearly of growing interest in the genetic dissection of human complex disease 
[249]. Despite advances in speed, the most common bench-mark for methods 
that detect epistasis remains simulated data, where single epistatic interaction 
embedded in a small number of SNPs is used to judge a method’s power and 
false positive rate under various parameter settings. In this work, I evaluated 
three statistical methods (PLINK, AntEpiSeeker and SNPepistasis) for detecting 
epistasis using a real life dataset. SNPepistasis was my novel method developed 
using a standard logistic regression framework while the other two methods were 
readily available from the literature.
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This study represents the first of its kind to compare the three methods using a 
real life dataset of SM. From a practical point of view, the main differences 
between these three methods were: the computational time required to complete 
the analysis and data manipulation before final analysis. From a methodological 
perspective, it is of note that PLINK, AntEpiSeeker and SNPepistasis detected 
the same top SNP pair despite different configurations of parameter settings. 
AntEpiSeeker employs an evolutionary computation non-exhaustive search 
strategy in comparison to the exhaustive search strategy of PLINK and 
SNPepistasis, it is a more satisfying outcome that the three methods produced 
similar results.
The top most significant interaction pair (interaction P= 1 .0x l0 '5) included the 
INPP4B  SNP rsl3103597 located on chromosome 4 and TNF  SNP rsl799964 
located on chromosome 6. The role of INPP4B  was discussed in Chapter 3 
section 3.4 while TNF  is a cytokine that is thought to play a major role in 
imparting pathogenicity to malaria [250]. It is also implicated in playing a 
central role in CM pathogenesis by inducing changes in cerebral endothelial cells, 
leading to the surface expression of adhesion molecules, thereby enhancing 
parasitized erythrocyte sequestration. It is worth noting that in the single-SNP 
assoc iation  analysis th e  INPP4B  rsl3103597 locus showed a significant 
protective effect (OR=0.82, P=7.57xl0 '6) against SM (Table 3.2), while no
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association was observed between the TNF  rsl799964 locus (OR=0.95, P=0.39), 
indicating that if I had focused on SNPs with main effect to test for interaction I 
would have missed this significant interaction. The same holds true for a recently 
published study of an exhaustive genome-wide analysis [251], whereby the study 
indicated that significant epistatic interactions would have been missed if SNPs 
that did not display any main effect had been excluded a priori [251]. However, 
it remains unclear whether this interaction would impact on disease progression. 
There is a need to explore the possible role of this interaction in malaria 
pathogenesis.
Previous studies have shown that an important causative protein in malaria is 
haemoglobin, which has two variants -  heterozygote HbAS and homozygote 
HbSS that can cause sickle cell anaemia. While HbSS is a lethal mutation 
leading to premature death, individuals with HbAS are protected against 
malaria. Additionally, there exist other mutations that can protect against severe 
and fatal malaria -  heterozygote - ol/ olol and homozygote - 0 / - 0 , which cause 
Q!+thalassaemia. A negative epistasis has been reported between HbAS and 
a+thalassaemia in a Kilifi Cohort [103] and this has been replicated in multiple 
studies (see Chapter 1 section 1.5.1.1). As a starting pointing in understanding 
the observed interactions results, I started by investigating this known epistasis 
interaction as a proof of principle. Interestingly, the present study confirmed
4.4 Discussion
145
this epistasis using a different design (case-control) to that used previously 
(cohort) [103], although the strength of association was rather weak.
To complement my results, I used STRING database [245] , to explore the wide 
spectrum of all biologically plausible authentic epistasis observed in my present 
study. Given the many hits in Table 4.1; it was a surprising fact that very few of 
them overlapped with the reported interactions evidence available in STRING. 
This paradox may be explained by: 1) some of these interactions represent 
statistical but not biologically plausible interactions; 2) the STRING database 
may yet have to be updated with evidence of these genetic interactions; 3) they 
might be novel epistatic interactions yet to be discovered. Nevertheless, the 
STRING tool demonstrated evidence of epistatic interactions among 
haemoglobin related proteins (HBA1, HBA2 and HBB) and some cytokines 
genes ( TNF., IL10, and IL13) relevant to malaria immunity. This is consistent 
with the conclusion that the STRING database is an important tool in 
interpretation of statistical data and in validating hypotheses of interaction 
between plausible genes [252].
In summary, I have compared and contrasted the performance of three selected 
approaches to identify epistatic interactions between SNPs using a real dataset 
of SM. While I have not conducted a comprehensive comparison in order to 
determine which method(s) performed the best for identifying interactions, each
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method has potential for application to high-dimensional genetic interaction data 
with any phenotype of interest. While this study has identified some interesting 
interactions, this remains a preliminary analysis at the beginning stage of 
applying epistasis using a candidate gene study. It must be emphasized here that 
it only included a small set of SNPs, and this could be a major limitation to 
drawing strong inferences about the epistasis observed if they are real. 
Nevertheless, they have served to illustrate the process and complexities of 
detecting epistasis. In Chapter 6, I will use a large-scale GWAS dataset to 
characterise the process of detecting epistasis interactions.
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Chapter 5
The haplotype structure and patterns of linkage 
disequilibrium across the HbS and a +thalassaemia  
3.7kb locus in the Kilifi population
Abstract
Surprisingly little work has been done to characterise the haplotype structure 
and LD patterns surrounding some of the well-known malaria susceptibility 
polymorphisms such as HbS and a +thalassaemia. One intriguing observation 
from the candidate gene case-control study (Chapters 3 and 4) was the 
protective and co-existence roles of these two variants in SM. This observation 
informed my decision to investigate comparatively their haplotype structures and 
their patterns of LD purposely to throw more light on how the two variants have 
evolved in the Kilifi population. First, I carried out a high-resolution analysis of 
the haplotype structure across a 1-megabase genomic region on chromosome 11 
using 1964 SNPs and across 300 kilobases on chromosome 16 using 210 SNPs. 
Next, I evaluated the extent of LD among biallelic markers surrounding the two
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variants using a correlation matrix and pair-wise LD measures (r2 and D'). To 
the best of my knowledge, this is the first study to comprehensively explore the 
haplotype structure and LD patterns of the HbS and a +thalassaemia variants 
that are found to co-exist in Kilifi. The findings described in this study may be a 
valuable resource for future functional studies designed to refine the genomic 
structure in both HbS and a +thalassaemia genomic regions.
5.1 Introduction
Recent DNA studies of modern human chromosomes have largely used patterns 
of modern genetic diversity to infer population histories, by applying simple 
models of chromosome evolution [253]. The evolutionary history is better studied 
by analysing haplotype of DNA sequences. Ultimately, there is great interest in 
understanding the haplotype structures in the human genome using identified 
genetic markers because: 1) haplotype structures may be used to infer the 
human evolutionary history and localise genetic variants underlying complex 
diseases ; and 2) recent advances in the high- throughput genotyping technology 
now make it increasingly possible to study millions of genetic markers in 
population samples of reasonable sizes [254]. Since the alleles at closely linked 
markers on a single chromosome are sometimes in LD, one important aspect is 
to identify the LD patterns in a region of interest or a population. LD patterns 
observed in natural population are the results of a complex interplay by many
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factors, including population history, recombination rates, gene conversion, 
natural selection, and other factors [255]. Therefore, it is not surprising that 
there is a much variation in LD among different genomic regions and population.
As reviewed earlier in the introduction Chapter 1, the HbS-rs334 and 
a +thalassaemia are inherited disorders of haemoglobin. HbS is a variant of the 
HBB gene located on chromosome 11 while the a +thalassaemia deletion is 
located on chromosome 16. These two chromosomes are highly polymorphic each 
with a high density of genes. Although biomedical research has accelerated its 
pace in the past decades, little has been done to look at how the haplotype 
structure and LD patterns can be utilised to aid our understanding of the 
dynamics of the malaria-driven selection of these two variants. Although, 
restriction fragment length polymorphism (RFLP) based haplotype analyses 
have been performed for both HbS and a +thalassaemia [256-258] along with 
looking at some sequences for short regions sequence data [259], little is known 
about how the two variants have evolved in the Kilifi malaria-endemic area and 
in larger chromosomal regions around the genes. Moreover, neither HbS nor 
a +thalassaemia are typed on the current GWAS chips. Having useful marker on 
the chips that are in LD with the causal variants could help infer/impute the 
HbS and a +thalassaemia genotypes, saving the time, effort and cost of direct 
genotyping, especially if the assays are non-trivial.
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5.1.1 O bjectives
The main objective of this chapter was to study the dynamics of evolutionary 
selection of HbS and a +thalassaemia gene regions. To achieve this goal, more 
specific objectives were set as follows:
1. Characterise the haplotype structure and sub-groupings within and between 
ethnic groups in the two gene regions.
2. Search for a functional SNP strongly correlated or with high LD with HbS or 
a +thalassaemia deletion.
5.2 Material and m ethods
5.2.1 S tu d y  p o p u la tio n
In order to capture most of the diversity in the Kilifi population, the study 
sample comprised of children with SM and healthy controls drawn from the 
Kenya GWAS study of SM (see Chapter 2, section 2.2.3).
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5.2.2 G enotyping and SN P selection
Samples passing the QC were genotyped using the Illumina HumanOmni2.5-4 
genotyping chip while identification of the a +thalassaemia genotype was done as 
described in chapter 2, section 2.2.1.3. To generate the datasets, I selected all 
common SNPs (>5% minor allele frequency) spanning in a 1Mb region on 
chromosome 11 and a 300kb region on chromosome 16. A total of 1,964 and 210 
polymorphic autosomal SNPs were included from chromosome 11 and 16 
respectively. The data has been phased so there were two haplotypes available 
for each individual, and two alleles at each SNP, encoded as 0 (reference) and 1 
(derived).
5.2.3 Statistical analysis
Genotype frequencies of the HbS and a +thalassaemia were determined by direct 
allele counting. Descriptive statistics was used for basic characterisations of the 
study population. The haplotype structures were analysed using the R function 
Hclust (http://cran.r-proiect.org/) for all subjects (cases and controls combined). 
To characterise the haplotype structure, individuals were used who were 
identified as being homozygous either for HbS, a +thalassaemia or having neither 
polymorphism. I did not use heterozygous individuals to reduce the chance of 
incorrect assignment of markers to haplotypes.
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Patterns of haplotype homogeneity in the chromosomes that have undergone 
selective pressure (HbS and - a )  were compared with the patterns in the non­
selected chromosomes (HbA and a a ) respectively. Genotypes were constructed 
from the haplotype data before computing pair-wise correlation coefficient 
matrix (r). The tag SNPs were selected based on evidence from the correlation 
matrix between the SNP and HbS or a +thalassaemia loci. Pair-wise LD was 
estimated by calculating pairwise D-prime (D') and R-squared (r2) metrics using 
customised R scripts. Principal component analysis (PCA), was used to 
determine the sub-structure within the Kilifi population. Receiver operating 
characteristic (ROC) curve analysis was used to assess predictive accuracy of 
chip intensiy data in predicting a +thalassaemia genotypes.
5.3 Results
5.3.1 General data of th e studied population
A total of 2,842 (both cases and controls) children were included: mean age 18.8 
(±20.2) months, 1383 (49%) were female and 1459 (51%) male. The study 
population comprised a variable mixture of three main ethnic groups: Chonyi 
32% (n=901), Giriama 51% (n=1459), Kauma 9% (n=258), and other 8% 
(n=224). Children belonging to other ethnic origin were excluded from further 
analyses.
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5.3.2 F requencies o f th e  H bS an d  a +th a la ssaem ia  p o lym orph ism s
Both HbS and a +thalassaemia polymorphisms occur at high frequencies in the 
Kilifi malaria-endemic population as shown in Table 5.1. The overall frequencies 
of HbAA and HbSS were 89% and 1% respectively while those of 
a a /a a  and -c/J-a  were 37% and 14% respectively. The frequency of HbSS was 
higher in Chonyi (2%) compared with Giriama (0.4%) and Kauma (0.8%) ethnic 
groups (Table 5.1) while the frequency of —aJ—a  genotype was slightly higher in 
Giriama (16%) subjects as compared to the other two ethnic groups (Table 5.1).
5.3.3 In ference  o f p o p u la tio n  s u b s tru c tu re
To investigate the relationship between the population structure and self- 
reported ethnicity, I performed a PCA analysis for all 2,618 individuals, and a 
two-dimensional plot based on the top two principal components (PCI and PC2) 
as shown in Figure 5.1a. I then coloured the plot according to ethnicity. As 
expected the first two (PCs), clearly separated the Chonyi, Giriama and Kauma. 
Nevertheless, some individuals could be confidently assigned to a specific ethnic 
group, whereas others seemed to have a complex ancestry. In Figures 5.1b and 
5.1c, I have only shown the homozygous HbS and a+thalassaemia individuals 
respectively used for the haplotype analysis. As can be seen, the majority of 
individuals are mostly separated from each other and located in the distinct 
ethnic groups; Chonyi, Giriama or Kauma.
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5.3.4 T he haplotype structure
Figure 5.2 shows the extent of homogeneity in the major haplotypes observed in 
HbS and HbA chromosomes in the samples analysed. The chromosomes are 
represented on the y-axis and 1,964 SNPs that were selected across the 1-Mb on 
the x-axis. For each SNP, the ancestral state is coloured black, while the derived 
allele is coloured white. I observed two features in the HbS chromosomes in this 
population, which may together be favourable for future genetics studies. First, 
the HbS chromosomes were extensively homogenous over the 1-Mb region 
though there seem to be two distinct haplotypes existing in this population 
(Figure 5.2). Second, examining the haplotype patterns there seem to be one 
‘common’ haplotype (200-kb region -part marked with a green box in Figure 5.2) 
around the HbS locus represented by the vertical red line. Common here means 
represented across the majority of chromosomes. The HbA chromosomes 
however, diversified essentially throughout the region as shown in Figure 5.2.
Figure 5.3 illustrates patterns of haplotype structure in the HbS and HbA 
cliromosomes observed in the study population stratified by the three major 
ethnic groups.. The most common HbS haplotype maintained its structure 
around HbS locus (200-kb region). Two major haplotype structures were 
observed for the HbS chromosomes in all the ethnic groups.
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Figure 5.4 shows the extent of heterogeneity in the major long-range haplotypes 
observed in a a  and - a  chromosomes. The location of the a +thalassaemia 
deletion in both plots is shown by the vertical red line. Unlike HBB, no apparent 
structure was observed in either a a  or - a  chromosomes across the 300-kb region. 
Figure 5.5 illustrates patterns of haplotype structure in the a a  and 
- a  chromosomes stratified by the three major ethnic groups. The haplotype 
patterns were not distinct among the three ethnic groups in the a a  chromosomes 
but some differences were observed in the - a  cliromosomes by ethnicity.
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F igure  5.2. Illustration of the haplotype structure in HbS and HbA 
chromosomes observed in the study population.
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F igure 5.4. Illustration of the extent of haplotype homogeneity in the - a  and 
a a  chromosomes observed in the study population.
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5.3.5 Correlation betw een neighbouring markers w ith  HbS or 
a+thalassaem ia
A detailed pairwise computation analysis using a correlation coefficient matrix 
(r) to search for SNPs with close correlation with the HbS or a +thalassaemia 
locus was performed. Figure 5.6 shows a correlation matrix plot between HbS 
(rs334) and the top 10 SNPs located in a 1015.3-kb region on chromosome 11. 
Pie charts were used to show the correlation for each SNP pair intersection. The 
colour intensity and size of each circle are proportional to the correlation 
coefficients, which ranged from -1.0 (a perfect negative correlation) to +1.0 (a 
perfect positive correlation). A correlation coefficient of zero signifies no 
association between two SNPs. As proposed by [260], the correlation levels were 
categorized as follows:
• 0 to 0.2: very weak to negligible correlation
• 0.2 to 0.4: low correlation
• 0.4 to 0.7: moderate correlation
• 0.7 to 0.9: strong correlation
• 0.9 to 1.0: very strong correlation
Out of the top ten SNPs, two SNPs: kgpl2988299 and kgpl2598517 which were 
56kb and 15kb upstream and one SNP: kgpl2698353 which was 229kb
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downstream of HbS were found to be moderately correlated with HbS (Figure 
5.6).
Figure 5.7 shows a correlation matrix between a +thalassaemia locus (thal) and 
the top 10 SNPs located in a 122.5-kb region on chromosome 16. The 
interpretation is the same as described above. Out of the top ten SNPs, three 
SNPs: kgp6975277, rsl 1248914 and kgpl6303049 which were 18kb, 70kb and 
87kb upstream of a +thalassaemia locus were found be low correlated with 
a +thalassaemia locus (Figure 5.7).
Another useful way for estimating the importance of the r value is to calculate 
the square of the correlation coefficient (r2). This squared result gives a rough 
percentage for the amount of variation between the parameters of interest. On 
this basis, I also calculated the r2 values and the results are given in the section 
that follows.
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F igure 5.6. A correlation matrix plot between HbS and top 10 most correlated 
biallelic markers.
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Figure  5.7. A correlation matrix plot between the a +thalassaemia locus and top 
10 most correlated biallelic markers.
CO
CO
CM
COlO
CMCO
CM
UO
CMo
CMh-(0
CM
G3h-OO
CO
"d"Q.
0 3
h~co
CO
CO
co"st
CD
Q .
0 3
h-h-"d-r-03
CM
CO
CD
f '- .h-
CMuoh~
0 3
COQ.
0 3
CD
CO
co
UO"d-
CO
Q.
0 3
-3sC
0 3
CO
"=t
CM
CD
CO
CO
0 3
CO
co
CO
0 3
"d-O
COo
CO
CD
Q.03-iC
rs2562188 
rs7202152 
kgp4800792 
kgpl6438637 
rs2974771 
thal
kgp6975277 
kgpl6451886 
rs11248914 
rs13339636 
kgpl6303049
•©0©Qrt,©0©0©l
©#©0©0©©0©©l
©©•0000©0©©l
000•00©0©0©l
00© 9 # 0 © © © © ©
00000#©0000
©00©00#©0©©
0©0©©0©•©00 r
000©000©#©©L
000O00©0©##|
O00000©0©##|
Colour intensity and the size of the circle are proportional to the correlation coefficients. Colour 
breaks occur a t 0.2 intervals. The markers are arranged according to  the position in chromosome 
16 region. T h a l= a +thalassaem ia locus
5.3 Results
166
5.3.6 Linkage disequilibrium  patterns
The purpose of a LD map is to tell us whether any two given SNPs are inherited 
together in an offspring. In other words, we want to know if any given SNP can 
determine the status of the other SNP. Figure 5.8 provides another view of 
examining the underlying LD structure among the 10 SNPs surrounding the 
HbS locus. Here the set of SNPs incorporated into the plot is the same as in 
Figure 5.6. The markers are arranged according to the position in chromosome 
11 region. Red squares represent high pairwise LD, colouring down to white 
squares of low pairwise LD. D' values from 0.7-1.0 indicate strong LD between 
pair of SNPs. Whereas D' value <0.7 indicates moderate LD and D’ value of 
<0.2 indicates no LD. D' is 1 when no recombination has occurred between two 
SNPs. The numbers in the individual squares are the r2 values multiplied by 100. 
When the minor alleles at two SNP positions are always present on the same 
haplotype, r2=100; when the minor alleles are always on separate haplotypes, 
r2=0. A strong LD pattern (r2=0.79, D’=0.94) was observed between the HbS 
locus and the kgpl2988299 SNP (Figure 5.8 squares marked with a black oval).
In contrast, examining the LD patterns between the a +thalassaemia locus and 
neighbouring SNPs does not exceed an r2 of 0.15 (Figure 5.9 squares marked 
with a black circle), inferring that, no correlation between the a +thalassaemia 
locus and neighbouring SNPs
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F igure 5.8. The pattern of linkage disequilibrium for ten SNPs surrounding 
the rs334 locus across a 1015-kb region of chromosome 11.
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F igure  5.9. The pattern of linkage disequilibrium for ten SNPs surrounding the 
cPthalassaemia locus across a 122.5-kb region of chromosome 16.
Physical Length:122.5kb
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The markers are arranged according to the position in chromosome 16 region. Red squares 
represent high pairwise LD, colouring down to white squares of low pairwise LD. D' values from 
0.7-1.0 indicate strong LD between pair of SNPs. W hereas D' value <0.7 indicates m oderate LD 
and D ’ value of <0.2 indicates no LD. The numbers in the individual squares are the r2 values 
multiplied by 100.
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5.3.7 Chip intensity data
From the above analyses it is clear that no apparent haplotype structure was 
observed in chromosomes carrying the a +thalassaemia deletion and 
notwithstanding, no individual marker SNP was found to be strongly correlated 
or with high LD with the a +thalassaemia deletion in this population. In the 
following analysis, I focused primarily on the a +thalassaemia locus, to examine if 
using the GWAS Illumina HumanOmni2.5-4 genotyping chip intensity raw data 
could shed more light on detecting the a +thalassaemia deletion.
Figure 5.10 is a scatter plot of the normalised intensity of the Illumina 
HumanOmni2.5-4 genotyping chip by a +thalassaemia genotype. Each point 
represents one individual’s genotype. The X-axis depicts the a+thalassaemia 
genotypes while on the Y-axis are the sums of the SNP X and Y channel 
intensities. Data for 6 SNPs are shown that span the 3.7kb oPthalassaemia 
deletion; rs2541670 and kgp3738253 are outside the deletion and rs2362744, 
rs2854120, rs4021965 and rs2858942 are internal to the deletion. It can be seen 
that there is a decrease in overall signal intensities in all a +thalassaemia 
homozygotes, although rs4021965 does not show this to the same extent as the 
other 3. There is also a decrease in intensities in heterozygotes.
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In order to test how well the intensity data may be used to determine 
a +thalassaemia genotype I have undertaken a combined regression analysis for 
the 3 SNPs rs2362744, rs2854120, and rs2858942, generated a ROC curve and 
determined area under the curve (AUC). Figure 5.11 presents a ROC curve 
showing the combinations of sensitivity (i.e true positive rate) on the vertical 
axis against and specificity (i.e false positive rate) on the horizontal axis for each 
possible cut-off value of the continuous chip intensity data that was used to 
predict the a +thalassaemia genotype. The results are depicted by bowed curves 
rising from the 45 degree line to the upper left corner -  the sharper the bend 
and the closer to the upper left corner, the greater the AUC, the greater the 
accuracy of predictions. From the Figure, we can see that the model was able to 
identify individuals who were homozygous wild-type (AUC=0.83), heterozygous 
(AUC=0.84) or homozygous (AUC=0.97) for a +thalassaemia by using chip 
intensity data.
5.3 Results
172
Het (AUC = 0.84) 
Homo (AUC = 0.97) 
Norm (AUC = 0.83)
F igure  5.11. Receiver operating characteristic curves using chip intensity data 
with respect to predicting the a +thalassaemia deletion.
o
0.4 0.6
False positive rate
The ROC curve presents the combinations of sensitivity (true positive rate) and specificity (false 
positive rate) for each possible cut-off value of the continuous chip intensity data  th a t was used 
to  predict the a +thalassaem ia genotypes. Chip intensity da ta  for three SNPs were used: 
rs2362744, rs2854120 and rs2858942. The dashed reference line represents the ROC curve for a 
test with no discriminatory ability. The area under the curve (AUC) is displayed in parentheses. 
The m agnitude of the AUC indicates whether the chip intensity d a ta  was useful in identifying 
individuals who were homozygous wild-type (AUC = 0.83), heterozygous (AUC = 0.84) or 
homozygous (AUC = 0.97) for cUthalassaemia.
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5.4 Discussion
There is growing evidence that haplotype structure may hold the key to 
understand better human evolutionary history and to identify more efficiently 
genetic variants underlying complex traits. Linkage disequilibrium has been 
observed over great physical distances at several genes experiencing recent 
balancing selection, including common variants implicated in resistance to 
malaria such as G6PD [149, 261-263], FREM3 [264], CD40L [72] and the HbS 
loci [265]. This has been escalated by the discovery of millions of SNPs. 
Characterising the haplotype structure and LD patterns of important genomic 
regions using SNPs is now an important strategy for mapping genes involved in 
complex human diseases such as malaria. These observations instigated me to 
investigate how two important variants that confer protection against SM have 
evolved in the Kilifi population where they co-exist in high frequencies.
The present study investigated the haplotype structure and the LD patterns of 
two important variants: HbS and a +thalassaemia in the Kilifi population. The 
results show that the frequencies of these two polymorphisms are indeed 
different among the three major ethnic groups. For example the frequency of 
HbSS was higher in Chonyi compared with Giriama and Kauma ethnic groups.
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Previous research into the origins of HbS have suggested that this allele may 
have arisen independently at least five times [266, 267]. The haplotype spans a 
region of about 60 kb. The distribution of these haplotypes gives rise to their 
names; Western Africa: Senegal and Benin; Central and Eastern Africa: 
Cameroon and the Central African Republic (also known as Bantu); and an 
Arabian-Indian haplotype [256, 268]. I have observed a single HbS haplotype 
spanning 200kb around the HbS allele which represents the Central African 
Republic type. However on inspecting the haplotype structure further out to a 
distance of 1MB on either side of HbS, it can be seen that there are at least 2 
major haplotypes and furthermore that these extended haplotypes are 
differentially represented between the local ethnic groups. Taken together this 
suggests that HbS arising in Central/Eastern Africa has moved between 
haplotypes in the local populations but maintained a core region. There are 
those who have questioned the multiple origins theory of HbS, saying the 
mutation could have spread to other haplotypes by certain unconfirmed 
processes, such as recombination and gene conversion [269-271] and therefore 
propose a uni-centric origin of HbS. My data clearly suggests that HbS can 
spread to different haplotypes but that it does so with common and large core 
haplotype in this Kenya group; although there are one or two haplotypes with 
variation in this core. As further GWAS datasets become publically available
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across Africa it will be possible to better explore the multi-centric versus uni- 
centric origin of HbS.
Conversely, no overall haplotype structure was identified for the a +thalassaemia 
locus. However, there did appear to be some structure related to ethnic group. I 
think that this is due to a combination of several reasons: a very old allele; time 
for recombination to break all LD down around the locus; time for it to spread 
onto other haplotypes and then LD to breakdown. Given the homologous nature 
of sequence covering the HBA genes it is thought that this deletion arises 
through a problem with homologous recombination. Therefore it is likely that 
the deletion has arisen several times [272], supporting this hypothesis. If this 
can happen more than once then it could happen on different haplotype 
backgrounds with time. Furthermore, the strength of effect on malaria is not 
large and therefore the length of haplotype is less likely to be long as in HbS.
A strong LD pattern (r2=0.79, D’=0.94) was observed between the HbS locus 
and the kgpl2988299 SNP. In contrast, no individual SNP was found to be 
strongly correlated or in high LD with the a +thalassaemia locus in this 
population. All this means that imputing a +thalassaemia locus could be difficult 
as there are not specific markers tagging the deletion unlike in HbS -  although 
in the latter regional specific tags are important and non-local specific tags will 
not be good [73].
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There are potential limitations in my study. First, the self-reported ethnicity 
could be creating wrong separation. Nevertheless, this form of classification is 
the one most probable to be encountered in real-life situations in the clinical 
practices. In addition, even self-reported ethnicity was able to differentiate 
clearly groups of individuals with rather different allele (HbSS and homozygous 
for a +thalassaemia). Second, the study population comprised only Kilifi 
population and thus the results cannot be freely applied to other populations. 
Nevertheless, to the best of my knowledge, this is one of the first studies to 
analyse the haplotype structure of the a +thalassaemia locus including examining 
the LD patterns and correlation between neighbouring markers. My results 
should help to refine the genomic structure in both HbS and a +thalassaemia 
genomic regions and to design case-control association studies involving the 
Kilifi population. Further studies on various regions across populations will 
facilitate the proper design of association studies of common complex human 
diseases. Studying the SNPs in LD is inspired by the observation that some loci 
are inherited together and may serve similar function.
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Chapter 6
A genom e-wide scan for loci interacting w ith  
known malaria susceptibility genetic variants
Abstract
Genome-wide association studies using the case-control study design have been 
used widely for finding epistatic interactions in complex diseases; however, to 
date, there have not been any genome-wide studies searching for epistatic 
interactions based on an infectious disease such as malaria. Through the 
MalariaGEN consortium, I have used an imputed GWAS data set that 
constitutes 9,189,809 SNPs, 1368 SM cases and 1474 controls in Kilifi, to 
investigate the process of detecting epistasis in SM. I have limited my search 
space to two well-characterised malaria susceptibility polymorphisms: HbS and 
a+thalassaemia in a logistic regression framework to search for interacting 
SNPs/genes. The principles of analysis were demonstrated using one model-pair 
for each of HbS and a+thalassaemia with the genome yet several interesting 
findings were made.
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One variant, rs4689899 (P=2.33xl0 '8) belonging to the STX18  gene on 
chromosome 4, and 3 variants: rsl50797078 (P=1.75xl0'8), rsll4945726 
(P=2.79xl0‘8) and rsll4274411 (P=2.79xl0 '8) in the vicinity of M YEO V  gene 
on chromosome 11 showed compelling evidence for interaction with HbS and 
oPthalassaemia respectively. This study represents the first GWAS to search for 
epistatic interactions with respect to SM. Accordingly, my findings here, while 
requiring further definitive replication, biological and functional validations, 
highlight some interesting novel interactions.
6.1 Introduction
Genome-wide association studies using SNP markers have identified many 
common genetic variants associated with common diseases. This has rapidly 
extended our knowledge of the genetic architecture of these diseases. 
Nevertheless, compared with the successes of single-locus approaches, the 
achievements of multi-locus interactions approaches, which seek susceptibilities 
that derive from gene-gene interactions, have lagged behind [204, 273]. Thus, 
gene-gene interactions that are largely undetected may explain some of the 
heritability of common diseases [274]. Most reported interactions related to 
malaria are currently found through candidate gene approaches, which 
incorporate prior biological knowledge and no attem pt has been made to identify 
joint genetic effects across the whole genome with malaria as the phenotype of
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interest. This is why I have taken advantage of the large amount of genetic data 
generated through the MalariaGEN consortium to conduct the first genome-wide 
interaction scan (GWIS) with respect to SM.
Detecting and analysing complex genetic epistatic interactions is not a trivial 
task, because of the computational difficulty created by the high number of 
possible interactions for even a relatively small set of candidate polymorphisms. 
For example, in the candidate gene case-control study in Chapter 4, I was 
studying ~114 SNPs in 71 malaria candidate genes. These 114 SNPs controlling 
for confounders yielded more than 50 possible two-pairs interactions. Nowadays a 
typical GWAS dataset contains many millions of genetic variations, making the 
enumeration of all pairwise SNP interactions computationally difficult, with the 
number of tests at hand increasing exponentially. This inevitably becomes a 
computational bottleneck when it comes to performing a GWIS. Two main 
strategies to detect epistasis have been proposed in the literature: 1) the 
conditional search, where at least one locus is fixed, and the other locus is 
random, and 2) the simultaneous search, which simultaneously scans all possible 
pairs of interacting loci [275]. Both strategies have been formally examined in 
linkage [276, 277], and association [236] analysis in humans. Due to the huge 
search space for complicated multi-locus interactions, I have applied a 
conditional search methodology.
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In Chapter 3, both HbAS and a +thalassaemia were independently associated 
with protection against SM as detected through heterozygous and additive 
models respectively. However, as seen in Chapter 4, instead of resulting in an 
even greater protective effect, co-inheritance of HbAS and a+thalassaemia 
resulted in a reduction in the individual protection afforded by each 
polymorphism. That said, apart from the interactions seen between HbAS and 
a+thalassaemia, are there any other important genetic interactions that might 
influence associations seen with malaria? For this reason, in this Chapter, I have 
given priority to these known susceptibility loci because they have been 
confirmed to be associated with SM risk in my previous analyses, to offer a clear 
picture on how to detect epistasis in humans using a GWAS study.
6.1.1 O bjectives
To date, no full GWAS interaction scans have been undertaken in malaria. As a 
main goal of this Chapter, I have limited my search space by conditioning on to 
two well-characterised malaria susceptibility polymorphisms: HbS and
a+thalassaemia and then run these in an interaction scan across the 9,189,809 
SNPs genome-wide. This allows the process to be looked into in more detail. To 
achieve this goal, more specific objectives were set as follow:
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1. To perform a QC on the GWIS analysis output through inspecting the 
distribution of the observed interaction P-values against the expected 
distribution under the null hypothesis.
2. To analyse any potential signals/hits in more detail including inspecting 
regions of interest and nature of epistatic effect.
6.2 M ethods
6.2.1 Study population
The same subjects and phenotype data from Chapter 5 were analysed in this 
Chapter. The study samples were collected as part of a genome-wide association 
study (Kenya GWAS) undertaken by the MalariaGEN consortium (see Chapter 
2, section 2.2.3). Some characteristics of the study population are described in 
Table 6.1.
6.2.2 GWAS genotyping and quality control
Both cases and controls were genotyped for 2,269,360 SNPs at the Wellcome 
Trust Sanger Institute (more details on genotyping and QC are given in Chapter 
2, section 2.2.1.3). SNPs that passed QC were 1,674,680 (74%) SNPs. 
Imputation using the phase 1 thousand genomes (1000G) reference panel 
extended the analysis to include 9,189,809 post QC autosomal SNPs. (see 
Chapter 2 section 2.3.1). All X-linked SNPs were excluded from this analysis.
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6.2.3 Statistical analysis
In order to test and demonstrate the process of undertaking a genome-wide 
interaction scan (GWIS), I ran the analysis with one fixed allele (reference or 
conditional allele) and used the genome-wide imputation data (>9 million SNPs) 
as the second allele. Given that for every pair of SNPs there are 25 possible 
interaction models (5 inheritance models per polymorphism; general, additive, 
heterozygote, dominant, recessive therefore 5 x 5 =  25 possible interaction 
pairs), I further restricted the analyses to 2 model-pairs. I selected 2 well- 
characterised protective signals in malaria as the conditional polymorphisms to 
represent these models (HbS for heterozygous and a +thalassaemia for additive). 
The second polymorphism in the interaction scan was used in an 
additive/general inheritance model. In summary:
• Interaction scan 1:
o polymorphism A: HbS locus (heterozygous advantage model)
o polymorphism B: genome-wide SNPs as an additive model
• Interaction scan 2:
o polymorphism A: a +thalassaemia locus (additive model)
o polymorphism B: genome-wide SNPs as an additive model
The test algorithm was SNPepistasis as described in Chapter 2 Section 2.3.2.2. 
This algorithm was further enhanced by adding a wrapper script by Dr. Gavin
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Band (see attributions). I fitted two models; a model that includes an 
interaction term, and a model that omits an interaction term, and in addition 
the top five significant principal components (PCAs) to control for population 
structure were included as covariates in each model.
The GWIS datasets were not submitted in one go, instead it was necessary to 
split the genome into ‘chunks’ of approximately 500kb before submitting to a 
high-performance Linux computing cluster at Wellcome Trust Centre for Human 
Genetics, Oxford. This was for computational efficiency and also not to over-run 
the memory capacity of each cluster node. In total 5733 chunks were submitted 
and one chunk took approximately 1.5 minutes to complete. The data were then 
subjected to several QC process as detailed below:
1. A Q-Q plot, which shows the distribution of the observed interaction P 
values of the logistic regression analysis against the expected distribution 
under the null hypothesis, was generated using the R statistical package 
(http: / / www.r-project.org). The genomic inflation factor (denoted X), was 
calculated by dividing the median of the observed %2 statistics by the median 
of the theoretical %2 distribution [278]. The inflation factor helps in detecting 
any population structure or genotyping error.
2. A common way of visualising the results of a genome-wide scan is to use a 
‘M anhattan plot’ or a detailed ‘regional plot’ of a region of interest.
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Manhattan plots were generated using the “mhtplot” function of ‘GAP’, a 
genetic analysis package for use in R {http: / Avww.inside- 
r.org/packages /cran/gap /docs /mhtplot) and regional interaction plots were 
created using LocusZoom ver 1.1 genetic analysis software [279], in which - 
loglO interaction P-values were plotted against their chromosomal positions.
3. Tables were generated based on the top ten hit regions. Information 
regarding the SNPs and genes functions included in these tables were sourced 
from SNP Annotation and Proxy Search (SNAP) [280].
4. Conditional logistic regression was used to assess the independence of 
interactions, reported for the top most plausible significant hit.
5. The commonly accepted genome wide significant threshold (P < 5 x 10-8) 
[281], which corresponds to a Bonferroni correction for the estimated one 
million independent markers was applied to report significant interaction 
results.
6. To aid interpretation of the results, the nature of the interaction was 
illustrated by Forrest plots showing genotype combinations. For each 
combination, an odds ratio from the logistic regression model was calculated 
by incorporating genotypes and fixed covariates.
6.2 Methods
185
6.3 Results
6.3.1 Characteristics of th e studied population
The basic demographic characteristics of the study populations are reported in 
Table 6.1 and are stratified by case-control status. The study included 1368 
case patients with severe malaria and 1474 controls. The median age (±standard 
deviation) of the cases and control children was 27± 23.5 and 7± 2.3 months 
respectively. Gender was balanced between cases (51% males) and controls 
(51.3% males). The proportions of SM cases with HbAS, - a / a a  thalassaemia, 
-aJ-CL thalassaemia were 3%, 47% and 12%, respectively. I performed two 
conditional GWIS to identify SNPs interacting with two malaria susceptibility 
polymorphisms: HbS and a +thalassaemia as fixed markers. Each of these scans is 
discussed in more detail below.
6.3 Results
Ta
bl
e 
6.
1.
 D
em
og
ra
ph
ic
 
ch
ar
ac
te
ris
tic
s 
of 
the
 
stu
dy
 
po
pu
la
tio
n 
in 
the
 
Ke
ny
a 
GW
AS
 
str
ati
fie
d 
by 
ca
se
-c
on
tro
l 
st
at
us
.
o
p+3aooCmO
£
41=
COCxi
-H
_
1—1 00 IDID v ^ Y—1--- 00b- CM 003D CM CMb- T—1 CM
'CP r—H 3DCO ID 1—1'y-3 v—3
30 co CO05 COOP b- CM
oCm 00s O 00 
CD
41=
iq
coCM
£CM
CMOb-
b-o
CO
i—1 CMP^ p^ \-1'—' v—-Y
CM OP P^T-1 05 3D3D 3D 1—1
<<
co
< COCO
B
B
.2+3o3’>o-B
'OP
cST3£
QCO
Pi
CD+3ocCpsAu
Qco
a
.2'd0>
0>W)
<
ffl
13
o
£
oT5fl
CD
o
£
o
£
oa^3+3o
0)bC
COJO
s
o
Z
aToa
Ofl0)6u0
CDBcw
co
13
6.3
 
R
es
ul
ts
187
6.3.2 HbS interaction scan across th e  genom e
After exhaustively fitting a conditional two-locus epistatic interaction scan across 
the genome between HbS as a fixed marker using heterozygous model and all 
other 9,189,809 SNP markers using additive model, I examined the distribution 
of the P-values from the interaction term. Figure 6.1 is a Q-Q plot showing that 
the distribution of interaction term p-values deviates from the expected uniform 
distribution under the null hypothesis of no epistasis (red diagonal line). These 
baseline deviations may suggest some interesting results. According to the plot, 
the genomic inflation factor is 1.02 suggesting that confounding factors such as 
population structure have been well accounted for in the interaction analysis. 
Under those conditions, I visualised the results using a Manhattan plot and 
plotted the SNPs on the x-axis according to their genomic position on each 
chromosome against the -loglO P-value of the interaction on the y-axis (Figure
6.2). I observed a strong epistatic effect (interaction P-value=4.42xl0'8) between 
the HbS locus and a marker (rs4689899) on chromosome 4 (the purple diamond) 
(Figure 6.2). Surprisingly, this was the only SNP to achieve statistical 
significance at the genome-wide threshold of -loglO P-value of 5 x l0 '8 (the solid 
red line, Figure 6.2). Several other loci (the red diamonds) demonstrated strong 
but not conclusive interaction evidence with the HbS locus (P c lx lO '6) (Figure
6.2). I further investigated the top ten most significant regions showing evidence
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of epistatic effect with the HbS locus (Table 6.2, A ppend ix  E, a n d  F igure  
E .l) . When encountering the same gene but with different SNP pair, only the 
SNP with the smallest interaction P-value was selected. The best interaction 
signal was the rs4689899 SNP (interaction OR=3.68 (2.32-5.85), interaction P- 
value=2.23xl0'8), located on chromosome 4 within the STX18  gene (the first 
region highlighted in blue, Table 6.2). This was followed by rs2586367 SNP 
(interaction OR=0.24 (0.32-0.85), interaction P-value=6.55xl0"7), located on 
chromosome 9 although not within or near any known genes (the second region 
highlighted in blue, Table 6.2). The third region, SNP rs57256359 (interaction 
OR=0.42 (0.22-0.81), interaction P-value=7.26xl0'7), located on chromosome 16 
within the JPH3 gene (the third region highlighted in blue, Table 6.2). Moreover, 
none of these genes have been implicated to have an association with SM. 
Details on the function and location of the top ten regions showing evidence of 
interaction with the HbS locus are in Table 6.2 and A p p en d ix  E , F igu re  E .l .  
For purposes of illustration, results presented hereafter are given only for the 
rs4689899 putative epistatic effect signal.
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F igure 6.1. Q-Q plot of the HbS interaction scan across the genome using 
heterozygous advantage model for HbS and additive model for the interacting 
SNP.
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The plot compares observed —loglO interaction p-values of the tested SNPs on the vertical 
axis to  expected —loglO p-values under the null hypothesis on the horizontal axis. Note the 
red line was used to indicate a  trend th a t data should follow. Baseline deviations suggested 
some interesting results. The lam bda value indicates the genomic control value for population 
stratification. The dotted black lines indicate the 95% CL
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6.3.2.1 Further exploration o f the rs4689899 interaction signal on chromosome 4
According to the HapMap phase 3 recombination maps, the locus of interest ,
rs4689899 is located in a region of chromosome 4 between two close 
recombination hotspots, and analysis conducted using the LocusZoom software 
demonstrated that no long range LD to rs4689899 exist within a 400kb region 
(Figure 6.3a). Further zooming into a smaller region (60kb) showed that the 
SNP was actually located inside the STX18 gene (Figure 6.3b). Among the 
SNPs in this region, two SNPs showed some evidence of interaction with the 
HbS, p-value <10~3 (A ppend ix  E, Table E .l) . These two SNPs were rs4689898 
that was 32 bases upstream and 4.14kb downstream rsll725796 of the rs4689899 
locus. Based on my data the rsl 1725796 (r2=0.76) and rs4689898 (r2=0.49) loci 
were in moderate LD with rs4689899. To evaluate whether or not the top 
interaction signal detected in the region was independent from the signal of the 
above two loci, I performed a conditional analysis. The epistasis interaction 
between the SNPs and the HbS locus was tested using a logistic regression 
model with and without conditioning on each one of the SNPs (rsl 1725796, 
rs4689898 and rs4689899). Conditioning on either of the SNPs (rsl 1725796 or 
rs4689898) evidence for an independent signal was found for rs4689899 locus (P 
< 10'7) (A ppendix  E , Table E .l) , suggesting that the strong evidence of 
interaction observed in rs4689899 locus was independent of rsl 1725796 and
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rs4689898 loci. I also examined the interaction pattern between the HbS and 
rs4689899 SNP pair using a Forrest plot. Figure 6.4 summarizes the ORs and 
sample size for each genotype combination relative to the reference genotypes.
In Figure 6.4, we can see that subjects who carry GG genotype for rs4689899 
and AS genotype for HbS have an increased disease risk compared to those who 
carry reference genotypes at both loci (rs4689899:GG/HbAA). However, for 
subjects who carry GA or AA genotype for rs4689899, carrying AS genotype for 
HbS significantly decreases the disease risk. For example, if there were no 
interaction effect, samples that carry GA or A A genotypes for rs4689899 would 
have an increased risk compared to the reference group. However, they actually 
have a statistically significantly decreased risk because of the interaction (Figure 
6.4).
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F igure  6.3. Regional interaction plot for the HbS interaction scan showing the 
top hit SNP rs4689899 located 011 Chromosome 4.
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Figure A) shows + / -  400kb around the rs4689899 locus, while Figure B) shows a zoomed in 
region + / -  60 kb around the rs4689899 locus. The diamond represents the top hit SNP rs4689899. 
SNPs are coloured based on their linkage disequilibrium (r2), w ith the rs4689899 SNP which had 
the smallest p-value in the region. The -log 10 P values for the SNPs are shown in the upper part 
of each plot. The bottom  section of each plot shows the fine scale recombination rates 
(continuous blue curve along the lower margin of the graph) estim ated from individuals in the 
Hapm ap population, and genes are marked by horizontal blue arrows and arrowheads. T he plot 
was produced using locusZoom software.
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6.3.3 A lp h a-th a lassaem ia  locus in te rac tio n s  scan  across th e  genom e
I further performed a GWIS conditional on a +thalassaemia as fixed effect and 
the other interacting SNP as random. Figure 6.5 shows the Q-Q plot of observed 
interaction p-values against those expected under the null hypothesis, indicating 
no evidence of spurious inflation (A,=1.04). Figure 6.6 shows the M anhattan plot. 
Examining the epistasis effect between the a +thalassaemia locus and the rest of 
the genome, three loci (rsl50797078, rsl 14945726 and rsl 142744113), located on 
chromosome 11 attained genome-wide significance threshold (Figure 6.5). A few 
other SNPs located on chromosomes 7, 9 and 15 also revealed some evidence of 
epistasis effect with the a +thalassaemia locus (points marked in red, Figure 6.5). 
Results of the top most significant regions showing evidence of interaction with 
the a +thalassaemia locus are presented in Table 6.3 and A p pend ix  E , F igure  
E.2, where the SNP id, gene name and its functions, p-value for interaction and 
as well as local plots of these regions are also listed. The best signals found 
clustered around M YEO V  gene with best interaction p-value of 1.75xlO'8 in 
rsl50797078 (Table 6.3), and 3 more SNPs around the same gene just short of 
the best interaction p-value. The second region with a peak showing evidence of 
interaction was found in rs8060012, chromosome 16, base position 12,906,971. 
This SNP was not within or near any known genes. The third region was SNP 
rsl0225502 located on chromosome 7 within the AVL9 gene (Table 6.3).
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F igure  6.5. Q-Q plot of the a +thalassaemia interaction scan using an additive 
model for the a +thalassaemia locus and the interacting SNP.
CO
CO
ao
ai0
1
k -  1.04
0)</>JOO
CM
O
2 30 6 74
Expected -lo g 1D(p)
The plot compares observed —loglO p-values of the tested SNPs on the vertical axis to  expected 
loglO interaction p-values under the null hypothesis on the horizontal axis. Note the red line 
was used to  indicate a trend th a t da ta  should follow. The dotted  black lines indicate the 95% Cl. 
The plot shows a slight deviation from the expected distribution (X=1.04).
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63.3.1 Further exploration o f  the rsl50797078 interaction signal on chromosome 11
In this section, I will only focus on the rsl50797078 locus which presented the
best evidence of epistatic interaction with the a+thalassaemia locus. The 
rsl50797078 is located in a region of chromosome 11 near the highest 
recombination hotspot in the region, and analysis conducted using the 
LocusZoom software exhibited some neighbouring SNPs with strong LD 
(r2=0.80) with this lead SNP within a 600kb region (Figure 6.3a). Surprisingly, 
further zooming into a smaller region (60kb) showed that the SNP was actually 
located outside of the M YEO V  gene (Figure 6.3b), leading to the question 
whether the signal was real or false positive. I further examined the interaction 
pattern for a+thalassaemia and rsl50797078 using a Forrest plot.
Figure 6.8 summarises the interaction ORs and sample size for each genotype 
combination relative to the reference genotypes. The interaction ORs of 
rsl50797078:AC/a+thalassaemia:-a/aa, rsl50797078:CC/a+thalassaemia:-a/aa, 
rsl50797078:AC/ a+thalassaemia:-a/-a and rsl50797078:CC/ a+thalassaemia:-a/- 
a  in Figure 6.8 were 1.06, 0.23, 1.56 and 0.47, respectively. This looks like an 
unusual interaction pattern. However, it is worth noting that the sample size was 
relatively small when the genotype of rsl50797078 was CC and as a result, all 
ORs estimates for these genotype combinations had large p-values and wide CIs.
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Figure  6.7. Regional interaction plot for the a +thalassaemia interaction scan 
showing the top hit SNP rs!50797078 located on Chromosome 11.
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Figure A) shows + / -  600kb around the rsl.50797078 locus, while Figure B) shows a zoomed in 
region + / -  60 kb around the r s l50797078 locus. The diamond represents the top hit SNP 
rs4689899. SNPs are coloured based on their linkage disequilibrium (r2), with the rsl50797078 
SNP which had the smallest p-value in the region. The -loglO P values for the SNPs are shown 
in the upper part of each plot. The bottom  section of each plot shows the fine scale 
recombination rates (continuous blue curve along the lower margin of the graph) estim ated 
from individuals in the Ilapm ap population, and genes arc marked by horizontal blue arrows 
and arrowheads. The plot was produced using locusZoom software.
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6.4 Discussion
With high throughput genotyping technology, SNP genotyping of a large number 
of individuals is becoming increasingly practical. Such large-scale SNP 
genotyping increases the effectiveness of association studies and provides an 
unprecedented opportunity to study complex genetic effects such as epistasis.
An important role of epistasis in the etiology of complex diseases in humans has 
been well recognized [247, 282-285]. Although there is appreciation that 
searching for epistasis in human may be a fruitful endeavour, it still remains a 
challenging task [274], due to the large number of SNP combinations needed to 
be tested and the sample sizes of the data sets particularly in the case of GWAS 
which are enormous. More importantly, the computational difficulty is the main 
bottleneck; detecting epistasis interaction requires a lot of memory and 
computational time. The most straightforward approach is to perform a 
simultaneous search that scans possible pair-wise combinations using some 
analytic approach. However, in GWAS, this is an intractable computational 
challenge.
In this large study, I have run a conditional two-locus epistatic interaction scan 
across the genome each for two malaria susceptibility polymorphisms: HbS and 
oc+thalassaemia as the fixed markers. To check that population structure was
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sufficiently accounted for by the inclusion of five PCs, I calculated the genomic 
inflation factor of the p-values in each scan and found them to all be less than 
1.05. The most significant interaction for the HbS scan was observed between 
the HbS and rs4689899 SNP-pair (interaction p=2.23xl0"8). The rs4689899 locus 
is located on chromosome 4 within the STX18  gene. This gene encodes an 
endoplasmic reticulum (ER) protein involved in protein transport between the 
ER and the Golgi apparatus [286, 287]. STX18  has also been shown to physically 
interact with proteins involved in the cell cycle and apoptosis [288]. A GWAS 
recently conducted by Cordell et.al [289], that included 1,995 cases with 
congenital heart disease and 5,159 controls, identified an association with the 
STX18 gene and susceptibility to atrial septal defects. The authors further 
suggested that the possible role of STX18  involved in regulating cell growth. 
Based on the available literature, this gene with regard to the risk of SM remains 
poorly defined.
Among the cCthalassaemia scan, the most promising interaction was between 
cCthalassaemia and rsl50797078 (interaction p=1.75xl0 '8). However, this SNP 
occurs at a low-frequency (9%) in my data so these findings should be 
interpreted with caution. Interestingly, the best 4 SNPs showing evidence of 
interaction were located on chromosome 11, though nearby the M YEO V  gene
6.4 Discussion
205
which plays a role in gastric cancer cell proliferation and invasion [290, 291]. So 
far, the function of this gene relating to SM has not been clearly defined.
As a starting point to understanding the process of detecting epistasis in humans 
using a GWAS study, I limited my search strategy to two well-known malaria 
candidate polymorphisms: HbS and cx+thalassaemia. The reasons of choosing 
these two polymorphisms were: their prominence in malaria; I was certain about 
their mode of inheritance for action (i.e. HbS-heterozygous and a+thalassaemia- 
additive); existing evidence of their known epistatic interaction that many people 
believe; and the fact that both polymorphisms co-exist at a high frequency in 
the Kilifi population. Given the known interaction between HbS and 
a+thalassaemia one might expect to see this signal in the two interaction scans 
that I have performed. However there was no signal in the HBA1/HBA2 region 
when conditioning on HbS. This is probably due to the fact that, the 
a+thalassaemia locus has not been imputed into the dataset or added to the 
GWAS dataset yet and also, as seen in Chapter 5, no clear markers were in LD 
with this locus to enable me to detect a signal. On the other hand, it would be 
more likely to see the interaction for the a +thalassaemia scan. And indeed I did 
observe a signal around the HbS locus although the signal was weak (P<0.08). 
This could may have been due to one of the following reasons; first, that there 
were few individuals in the HbS group leading to a loss of statistical power to
6.4 Discussion
206
detect the signal; second, that the a + th a la s sa e m ia  interaction scan was not the 
correct model (additive x additive) for detecting the HbS signal. The best model 
would have been additive for the a +thalassaemia locus and heterozygous for the 
HbS locus. So overall it is not particularly surprising that, I did not observe a 
stronger interaction association signal between the two loci. .
Although both GWIS pointed to potential epistasis interactions, it is worth 
pointing out that only two genetic models were applied: for the conditioned loci. 
For future applications, a model selection technique needs to be developed to 
determine the most appropriate model with the least loss of power. While not all 
epistatic effects are likely to follow heterozygous or an additive model, they were 
chosen since they were the best models associated with protective effect for HbS 
and o+thalassaemia respectively (see Chapter 3). There is still no agreement in 
the literature about the most efficient way to perform a GWIS. A number of 
statistical methods are applicable to the detection of such interactions [204, 292- 
295] and none of them could be considered the best. Comparing the 
performances of different methodologies is of great importance but out of the 
scope of this chapter. In the present study I focused on the application of a 
standard methodology, the logistic regression model, that has been shown to be 
a valid methodology for detecting interaction between SNPs [204]. This study 
had several methodological and technical advantages in addition to the above
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interesting findings. (1) To my knowledge this is the first genome-wide study to 
explore how SNP-SNP interactions influence severe malaria risk. (2) The sample 
size included in this study is large enough to increase the power of detecting any 
epistasis interaction if any. (3) My analytical approach embraced inclusion of 
covariates which provides a more accurate estimate of the interaction effects in 
SM. (4) These data is part of a GWAS undertaken by the MalariaGEN 
consortium, indicating that my observed interactions can easily be validated 
[200]. My study had several limitations. (1) I used the conditional search 
strategy, where at least one locus was fixed and the other locus was random for 
the interaction analyses, I could have missed significant interactions between all 
possible SNPs pairs (i.e. pair-wise comparisons). (2) The small cell size in the 
interaction analyses might introduce false positives. (3) My approach is data- 
driven (statistical epistasis), without utilising any existing biological knowledge 
(e.g., pathways analysis, networks, and other functional annotation data), which 
may reduce the statistical power and interpretation of my results. That said, the 
use of this methological approach should be considered as only one step in 
detecting epistatic interactions in a GWAS. Considerable work still may be 
required for digesting the test results. Nevertheless, if one can successfully 
identify a real epistatic interaction; I believe that it will give important clues to 
the understanding of the underlying biology of human complex traits such as 
SM.
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Chapter 7
Discussion and conclusions
This chapter concludes this thesis, discusses the contributions this thesis makes 
and considers future directions.
7.1 Statem ent of contributions
Over the last decade, the study of the genetics of infectious disease susceptibility 
has undergone substantial revolutionary change [296]. The wealth of information 
that can be gleaned from the completed map of the human genome coupled with 
rapid advances in genotyping technologies has presented many opportunities and 
avenues for scientist to test many long-held assumptions about the 
pathophysiology of complex human disease such as malaria. This has spawned 
new areas of specialization in genetics and new methods for the analysis of the 
genomic data.
In this context, the first contribution of this thesis was in the area of confirming 
previously proposed associations between malaria candidate genes and SM and 
its major sub-phenotypes (CM, SMA and RD) by comparing a group of children
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with these phenotypes with healthy controls. This line of work was motivated by 
a large-scale characterised case-control study of severe P. falciparum  malaria, 
which contained 121 loci (of these, 65 were previously published associations 
while 56 were new hits identified in a recent GWAS undertaken by the 
MalariaGEN consortium) in 71 malaria candidate genes including 
a +thalassaemia for 2,245 cases and 3,949 healthy controls. This case-control 
study was carried in Kilifi County, in Kenya, and it was undertaken as part of 
the MalariaGEN Consortium Project 1 (CPI) [45]. Being part of a consortium 
that set out standardised phenotypic definitions and high quality genotyping 
data made the design, assembly and analysis of the study easier.
This is the largest case-control study of malaria that has yet been conducted in 
Kilifi. This large sample size allowed me to investigate the heterogeneity of the 
effect of malaria resistance loci in greater detail than has previously been 
possible. Single SNP association analysis using the 121 polymorphisms 
including a +thalassaemia revealed twenty-five loci that were strongly associated 
with SM and its major sub-phenotypes. Out of 71 candidate genes investigated, I 
observed that polymorpliisms affecting various aspects of RBC (including HBB , 
HBA , G6PD, FREM3, INPP4B , ATP2B4 and ABO) were among those 
associated with the strongest signals of differential susceptibility to SM. These 
genes cover surface proteins that have been shown/suggested to aid parasite
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invasion. All these genes, including a new one (ATP2B4) that was recently 
identified to play a role in calcium ion exchange across the RBC membrane, 
their mechanisms of malaria protection have not yet been fully elucidated for 
any; however, with overwhelming evidence that they are important, perhaps this 
will encourage more RBC related work to understand how humans fight malaria 
but also lead to new treatments/drugs to fight malaria. This study and a recent 
report published by the MalariaGEN [45] confirm that most of markers
associated with SM are related to RBC and whether there are other markers
with the evidence is something worth debating. Some of the RBC markers had 
strong effects in all phenotypes which is suggestive of a common growth-
inhibitory effect. Previous studies have suggested that some of the traditional
candidates might be associated with specific effects against particular sub­
phenotypes of malaria. In this study however, there was little to suggest that 
this is true for most of the candidates, including a+thalassaemia which others 
[16, 41, 62, 66] have previously suggested might be particularly protective 
against anaemia. The explanation for this discrepancy probably relates to the 
sample size of these previous studies have been relatively small. In addition, to 
the traditional candidates, in this study, I have confirmed the associations of 
ATP2B4 [230] gene, which is a membrane calcium transport protein, FREM3 
gene, which is an extracellular matrix protein which may play a role in cell
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adhesion but little is known on severe malaria and INPP4 B ,which is a protein 
binding gene. These are immediate neighbours to the GYPA, GYPB, GYPE 
region and more likely markers for that region (MalariaGEN personal 
communication and manuscript under review [213]). These candidates have also 
been replicated in another MalariaGEN study site in Tanzania [297] and may 
potentially provide interesting targets for learning about malaria biology and 
developing new treatments.
Other major polymorphisms of immune mediators such as cytokines and their 
receptors did not replicate in this study. For example, in my study, 110 
association between SM with ICAM1 gene was observed. This is in agreement 
with the results reported by a study in The Gambia, Malawi and Kenya [106]. 
Such heterogeneity of effect should be kept in mind when judging the lack of 
replication of many reported SNP associations to disparate malaria clinical 
manifestations [298, 299].
In a previous study conducted in Kilifi, it has been estimated that inherited 
factors might account for as much of 35% of the variability in the risk of severe 
malaria [34]. Typing for a large number of candidate genes gave me the 
opportunity to re-visit this question using a different approach. I found that the 
proportion of the total variation in the risk of SM that can be explained by the
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polymorphisms that were associated with a significant effect in the current study 
was only 7.6%, suggesting that additional genes are yet to be discovered. This 
was derived from an ascertained set of SNPs and with the current GWAS's 
under analysis this can be estimated across the whole genome across several 
MalariaGEN sites.
Part of the motivation for the recent enthusiasm for looking for genetic 
interactions underlying the human disease is the sense that previous failures to 
identify and especially to replicate, significant individual genetic associations 
might be driven by underlying complexity generated by epistasis [283]. Given 
this rapid increase in the size and precision of human association studies, we are 
now entering an era in which we can rigorously address the hypothesis of 
whether failure to replicate these associations was due to genetic complexity. The 
second contribution of this thesis was therefore in the area of investigating 
whether the malaria candidate genes discussed above were acting independently 
or whether some of them interact to bring about protection. Most of the 
reported epistasis between malaria candidate genes has been investigated in 
small studies using data on a limited number of genes. To my knowledge, this is 
the first large-scale case-control study of SM to investigate epistasis between 
multiple candidate genes. In the present study, I investigated epistasis by 
applying three computational algorithms: PLINK, AntEpiSeeker and
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SNPepistasis. I compared and contrasted the performance of these three 
approaches. All the three methods selected the same topmost hit SNP pair, and 
additional significant epistatic interactions were observed. While the three 
methods confirmed the previously reported epistatic interaction between HbAS 
and a+thalassaemia the strength of association was rather weak, perhaps for 
reasons of study design. The combination of the strong protective effect of HbAS 
and the relative rarity of compound heterozygous individuals meant that even a 
study of this size included few individuals in the combined groups, resulting in 
limited power.
Searching and reporting epistasis results involve two major challenges. First, 
since an enormous number of possible combinations are tested, a large 
proportion of significant associations might be false positives. In this case, I 
validated my results using STRING, a database of known and predicted 
protein-protein interactions [245]. By using this established biological database, I 
might miss novel epistasis interactions between genes; nevertheless the 
interaction models with detectable statistical epistasis, having enough biological 
evidence has a high likelihood of being interpretable. The second major 
challenge involves interpretation of the results and developing them into 
biologically meaningful hypotheses. For this reason, I focussed on HbAS and 
a+thalassaemia epistasis interaction that I believe to be true because it has
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been repeated in multiple populations from Kenya, Ghana and Mali [57, 62, 
103]. In the light of this observation, as a third contribution of this thesis I 
investigated the dynamics of evolutionary selection of HbS and a+thalassaemia 
genomic region. It is possible that an apparent association with malaria can arise 
from LD between the typed SNP and a primarily associated polymorphism. 
Constructing a detailed haplotype structure map of polymorphism around these 
candidate genes and describing a profile of LD among them will be helpful to 
identify the causal variants(s). Also since neither HbS nor a+thalassaemia are 
typed on the current GWAS chips having a useful marker on the chips in LD 
could help determine the HbS and a+thalassaemia genotypes savings us time, 
effort and cost on direct genotyping especially if the assay is non-trivial. To 
display the haplotype structure, I decided only to show homozygotes as the data 
has been phased and was possible that the heterozygous individuals for these 
loci have not been assembled correctly. I compared patterns of haplotype 
homogeneity in the chromosomes that were homozygous for HbS (HbSS) and 
homozygous for a+thalassaemia (-a /-a ) with those of homozygous wild type for 
HbS (HbAA) and homozygous wild type for a+thalassaemia (aa/aa) 
respectively.
The results of the study indicate that in Kilifi, the HbS allele shows clear 
evidence of recent positive selection. It lies on haplotypes that are significantly
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less diverse than those for the wild type HbA allele. The signature of recent 
positive selection observed in the HbS haplotype raises critical questions on how 
they can be explored in doing the predictions, and the effect of other mutations 
in the HbS haplotype on its anti-malarial properties and disease intensity in 
different climatic conditions in Africa. The differences in the HbS haplotypic 
backgrounds observed here is also a reminder of the unresolved debate on the 
origins of HbS mutation. Conversely, no apparent structure was seen in either 
the a a  or - a  chromosomes across the 300-kb region. Nevertheless, some 
differences were observed in the - a  chromosomes by ethnicity. These findings 
suggested that the - a  allele might be an ancient allele that has undergone a 
breakdown in haplotype structure by recombination or that the mechanism of 
deletion due to the homology in the sequences across the HBA region has 
occurred many times. Further, exploring the LD patterns showed a moderate 
level of LD with the HbS locus, but no individual SNP was found to be 
correlated or in high LD with the a+thalassaemia locus in this population. 
Based on this observation, I extended my analysis to look at the raw chip 
intensity data to try and predict the a+thalassaemia genotypes. Given that 
a+thalassaemia is an important associated gene in malaria then any GWAS 
should find a way to type it to allow a full catalogue of genes to be included. 
Also it will allow further work including epistasis.
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Finally, since the central theme of this thesis has been epistasis between malaria 
candidate genes, I further explored and illustrated how to search for and 
evaluate epistatic interactions in a GWAS study. Although there is appreciation 
that searching for epistasis in humans may be a fruitful endeavour, it still 
remains a challenging task [274], due to the large number of SNP combinations 
needed to be tested and the sample sizes of the datasets particularly in the 
context of GWAS studies. To deal with these challenges, as a starting point, I 
limited my search space to the HbS and a+thalassaemia polymorphisms in a 
logistic regression framework using one genotypic model for each pair. The study 
involved 9,189,809 SNPs, 1368 SM cases and 1474 healthy controls from Kilifi 
population. The most significant interaction for the HbS scan was found between 
HbS and the rs4689899 locus within the STX18 gene, an endoplasmic reticulum 
(ER) protein involved in membrane trafficking between the ER and Golgi, on 
chromosome 4. Conversely, the most promising interaction in the a+thalassaemia 
scan was with the rsl50797078 locus located on chromosome 11, close to the 
MYEOV gene that plays a role in gastric cancer cell proliferation and invasion. 
So far, the role of these two genes (STX18 and MYEOV), if any, with regard to 
the risk of SM remain poorly defined. Furthermore, I have only explored a small 
snapshot of the epistasis space to understand the process of detecting epistatic 
interactions using data from a large scale genome-wide study. Apart from
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validating and replicating the results, there is more work to be done including 
pair-wise interactions of potential signals and also performing a full genome wide 
interaction scan taking into account all the models of inheritance.
This study had some limitations. First, the sampling was not representative 
across all ages. The majority of the data were from young children under the age 
of 5 years; reflective of the general burden of malaria disease among young 
children in the study area. Second, while this study identified some interesting 
interactions, it must be emphasized that they have not yet been validated and 
this could be a major limitation to drawing strong inferences about the epistatic 
interactions observed and whether they are real.
7.2 Future directions
Although the work presented here is a detailed interrogation of malaria 
candidate genes, there are still avenues that have been left unexplored. The 
single-SNP association analysis depicted some intriguing findings. The study has 
power to look at the effects on mortality and parasite densities on the protection 
afforded by the malaria candidate genes included in the study. Another 
interesting observation was the proportion of variance explained by these 
candidate genes additively on malaria risk. It will be interesting to see the
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proportion explained by including their interactive effects and extend it to 
GWAS.
Considering further work relating to epistasis detection, there are multiple folds: 
First, epistasis models used in this study were limited to heterozygous and 
additive effect for the genome scan. The full epistasis space still needs to be 
explored for the other genetic models of inheritance. Second, the obvious next 
step for these analyses is to link the network structure revealed by epistasis 
analysis to information obtained from other methods, such as biological network 
and build a comprehensive map of the full interactions. Given the computational 
challenge, rather than conducting a full genome wide interaction scan, 
concentrating on a set of genes known to be functional in protection from 
malaria, offers a promising way forward. For example, Collins et. al [300] used all 
pair-wise interactions of 743 genes known to influence chromosomal processes 
such as DNA repair, transcription regulation, and chromatid segregation in 
yeast. This enabled them to place their epistatic interaction results within the 
context of already well-explored systems. In this respect, their epistatic 
interactions corresponded well to known physical interactions among proteins, 
nonetheless allowed novel interactions to be discovered above what would 
otherwise be a chaotic set of more than half a million potential epistatic 
interactions. In my future analysis, I will concentrate on RBC polymorphisms
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and examine their joint effects on SM and other major sub-phenotypes. Third, in 
order to validate some of the observed epistasis, it is my long-term goal to 
collaborate with the MalariaGEN consortium for further experimental 
verification and further biological interpretations.
Finally, since this is the first study to characterise the haplotype structure and 
LD patterns of the HbS and a+thalassaemia locus in Kenya it would be more 
fascinating to investigate the age of these two alleles, purposely to throw more 
light on how they have evolved in the Kilifi population. Studying haplotype 
structures and the chip intensity data are also important as they may identify 
markers or ways to identify some of the more complex markers that are 
implicated in malaria. These are not necessarily represented on GWAS chips; 
deletions such as a+thalassaemia, GYPC, SLC4 AI (Band3), all of these are 
important to validate and should be annotated within GWAS studies to be able 
to fully investigate the genetic contribution to malaria resistance.
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Appendix B
SNPepistasis -Pseudocode for Chapter 2
Appendix B
2 2 5
B . l  S N P e p is ta s is  — p se u d o c o d e .
#  # # #  #  #  # # # # # # # # # #  # # #  # #  # # # # # # # #  // # # # # # #  #  # # # #  # # # # # # # / /  # # # # # # #  
# # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # #  
options(help_type='textn)
as.numeric.factor <- function(x) {as.numeric(levels(x))[x]} 
fNumeric= function(temp) as. numeric(as. vector (temp))
fSNPdataModel=function(snp.models general")! 
if(model=’general"){ 
snp=as.factor(snp)
}
if(model="additive") { 
snp=as. integer (snp)
}
if(model="het"){
snp[snp!=l]=0
}
if(model=" dominant") { 
snp[snp!=0]=l
}
if(model=" recessive1) { 
snp[snp<2]=0 
snp[snp=2]=l 
}
snp
}
# #  set working directory ///) / ///  //// # / / / / / /  //://// // // # # # # # # # # # # # # # # # # # # # # # # # # #
Home=" /data/bayes/users/cndila/2015/Metliod2 / "
setwd(home)
# #  Read data with all the 16 models # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # #
modelSpec=read.table('Models.txt\ headei-T)
modelSpec[,2]=as.cliaracter(modelSpec[.2])
modelSpec[,3]=as.character(modelSpec[.3])
no.modelSpec=dim(modelSpec)[l]
# #  Read data the genotype data and fit the
r e g r e s s i o n # # # # # # # # # # # # # # # # # # # # # # # # # # # #
db=read.csv(' Data__2014.csv", headei=T)
output.file="output.txt"
outputMinimum.file="outputMin.txt"
c.range=dim(db) [2]
Case=db$CASE 
D=db[.-c.range]; # D  D j .  ! :'> /  
snps.names = names(D) 
n.snps = lengt h(snps. names) 
snps.names.il = snps.names[-n.snps] 
iCount=0
result = data.lfainc();result.min = data.ffameQ 
for(supl.name in snps.names.il) { 
iCount=iCount+l
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snp 1=D[, snp 1 .name]
catCRunning interaction scan of ", snpl.name, ' (i.e. ". iCount, ' of ", n.snps. ") with otlier 
snps...\n",sep="")
j = which(snpl.name=snps.names)+l 
for(snp2.name in snps.names[j:n.snps]) { 
snp2 = D[,snp2.name]
modelSNPs=paste(snpl. name, "*",snp2. name, sop="") 
this.result.min = ebind(ModelSNPs=modelSNPs.
count_00=length (which (snp 1 = 0  k  snp2=0)), 
count_01=length(which(snpl=0 k  snp2= l)), 
count_02=length(wliicli(snpl=0 k  snp2=2)), 
count_10=length(which(snpl==l k  snp2=0)), 
count_ll=leugth(which(snpl=l k  snp2= l)), 
count_12=length(which(snpl==l k  snp2=2)), 
count_20=length(which(snpl=2 k  snp2=0)), 
count_21=length(which(snpl=2 k  snp2= l)), 
count_22=length(which(snpl=2 k  snp2=2)), 
interaction. P . min=N A 
) i f  e n d  c b i n d  
print (snp2.name) 
this.result=NULL
for (modelNo in l:no.modelSpec){ - i f o r  m o d e l N o  
modelSpecl=modelSpec[modelNo.2] 
modelS pec.2=modelSpec[modelNo.3] 
snp 1 M=fSNPdataModel(snpl ,modcl=modelSpec 1) 
snp2M=fSNPdataModel(snp2,model=modelSpec2) 
modelSpecs=| >aste(modelSpec 1 ,modelSpec2,sep="") 
tryCatch({
g=glm(Case~snplM*snp2M.family='binomiar)
d=drop 1 (g ,scope=g$ for mula, test=" L RT') 
this.result=rbind(this.result, cbind(ModelSNPs=modelSNPs.ModelSpecs=modelSpecs. 
mPvall= df'snplM'. 'Pr(>Chi)'].mPval2= d['snp2M', 'Pr(>Chi)'], 
iPval= d['snplM:snp2M'.'Pr(>Chi)']))
},error=function(e){print(e);}) • e n d  t r i j C a t c h  
} #  e n d  f o r  m o d e l N o
this.result=data.frame(this.result[,l:2],apply(this.result[,3:5],2.fNumeric)) 
index. min=which(this.result$iPval=min(this.result$iPval)) 
result.min = rl )ind(result,tliis.result[index.min,]) 
result = rbind(result.this. result)
} #  e n d  o f  s n p S . n a m f  f o r  
}  f f  e n d  o f  s n p  I n a m e  f o r
# #  Saving minimum pvalues of the models # # # # # # # # # # # # # # # # # # # # # # # # f t # # # # # # # #  
cat( "Saving results to \ " ,  outputMinimum.file, "\"...\n", sep = "" ) 
write.csv(result.min. file = output_minimum.file. row.names = F, quote = F )
# #  Saving the all the results # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # #
cat( "Saving results to \ " ,  output.file, "\"...\n". sep = "" )
write.csv(result, file - SNPepistasis_output.file, row.names = F. quote - F )
# #  Viewing the top 100 most significant pvalues # # # # # # # # # # # # # # # # # # # # # # # # # # # # # #
cat( "Complete. Top 100 most significant interaction P-values:\n". se])="")
options(width=300)
result.min= result.min[ordcr(as.numeric.factor(result.min[,"iPval"]), decreasing = F ), ] 
print( result.min[l:100,] ) 
cat( "bye!\n" )
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Figure C .l. Shows the distribution of minimum p-values from the genotypic 
tests of inheritance.
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Figure D . l .  A Manhattan plot for all pairs epistatic interactions detection using 
the 3 methods.
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The dashed line represents a p-value threshold of <0.003. The X-axis depicts -log  p-value and the 
Y-axis are the SNPs pairs.
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Figure E .l  The top ten significant regions of the HbS interaction scan across the 
genome.
Region 1. A regional plot and a Forrest plot of interaction between HbS and rs7515285 on
chromosome 1.
p w w s u f t  i m m  i t n i i  m i  h i  i i i h  i n  I  i  m i  i i i  n i ' i Mi i  i i d  n r
i)
I
3^S
0
AAr~
TT CC 
rs7515285
— r ~
CT
R e g io n  2. A regional plot and a Forrest plot of interaction between HbS and rs2973697 on 
chromosome 5.
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R e g io n  3. A regional plot and a Forrest plot of interaction between HbS and rs2290471 on 
chromosome 8.
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The left panel shows + / -  400kb around the top hit SNP, which had the smallest p-value in the 
region. SNPs are coloured based on their LD (r2), w ith the the top hit SNP. The -loglO P  values 
for the SNPs are shown in the upper part of the plot. The bottom  section of the plot shows the  fine 
scale recombination rates, and genes are marked by horizontal blue arrows and arrowheads. The 
right panel is a  Forrest plot showing interaction pattern  between HbS and the top hit SNP. For 
each combination of genotypes (x-axis), I com puted the odds ratio  ±95% CI (y-axis). The red line 
shows the point of no effect.
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R egion 4. A regional plot and a Forrest plot of interaction between HbS and rs7220613 on
chromosome 17.
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R e g io n  5. A regional plot and a Forrest plot of interaction between HbS and rs7247679 on 
chromosome 19.
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R e g io n  6. A regional plot and a Forrest plot of interaction between HbS and rsl49664178 on 
chromosome 19.______________________________________________________________________________
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The left panel shows + /-  400kb around the top hit SNP, which had the smallest p-value in the 
region. SNPs are coloured based on their LD (r2), w ith the the top hit SNP. The -loglO  P values 
for the SNPs are shown in the upper part of the plot. The bottom  section of the plot shows the 
fine scale recombination rates, and genes are marked by horizontal blue arrows and arrowheads. 
The right panel is a Forrest plot showing interaction pattern  between HbS and the top hit SNP. 
For each combination of genotypes (x-axis), I com puted the odds ratio ±95% CI (y-axis). The 
red line shows the point of no effect.
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Region 7. A regional plot and a Forrest plot of interaction between HbS and rs2586367 on
chromosome 9.
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R e g io n  8. A regional plot and a Forrest plot of interaction between HbS and rs57256359 on 
chromosome 16.______________________________________________________________________________
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R e g io n  9. A regional plot and a Forrest plot of interaction between HbS and rs28409311 on 
chromosome 16.
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The left panel shows + / -  400kb around the top hit SNP, which had the smallest p-value in the 
region. SNPs are coloured based on their LD ( r ) ,  with the the top hit SNP. The -loglO P  values 
for the SNPs are shown in the upper part of the plot. The bottom  section of the plot shows the 
fine scale recombination rates, and genes are marked by horizontal blue arrows and arrowheads. 
The right panel is a Forrest plot showing interaction pattern  between HbS and the top hit SNP. 
For each combination of genotypes (x-axis), I com puted the odds ratio ±95% CI (y-axis). The 
red line shows the point of no effect.
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F i g u r e  E . 2 .  T h e  t o p  t e n  s i g n i f i c a n t  r e g i o n s  o f  a +t h a l a s s a e m i a  i n t e r a c t i o n  s c a n .
Region 1. A regional plot and a Forrest plot of interaction between a +thalassaemia and
rs!0924388 on chromosome 1.
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R e g io n  2. A regional plot and a  Forrest plot of interaction between a +thalassaem ia and 
rs7648169 on chromosome 3.
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R e g io n  3. A regional plot and a Forrest plot of interaction between a +thalassaem ia and 
rs4505829 on chromosome 4.
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The left panel shows + / -  400kb around the top hit SNP for the cPthalassaemia GWIS, which had 
the smallest p-value in the region. SNPs are coloured based on their LD (r2), w ith the the top hit 
SNP. The -loglO P values for the SNPs are shown in the upper part of the plot. The bottom  
section of the plot shows the fine scale recombination rates, and genes are marked by horizontal 
blue arrows and arrowheads. The right panel is a Forrest plot showing interaction pattern  
between HbS and the top hit SNP. For each combination of genotypes (x-axis), I com puted the 
odds ratio  ±95% CI (y-axis). The red line shows the point of no effect.
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R egion 4: A regional plot and a Forrest plot
rs4479863 on chromosome 5.
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R e g io n  5. A regional plot and a  Forrest plot 
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The left panel shows + /-  400kb around the top hit SNP for the a 1 thalassacm ia GWIS, which had 
the smallest p-value in the region. SNPs are coloured based on their LD (r2). w ith the the top hit 
SNP. The -loglO P values for the SNPs are shown in the upper part of the plot. The bottom  
section of the plot shows the fine scale recombination rates, and genes are marked by horizontal 
blue arrows and arrowheads. The right panel is a Forrest plot showing interaction pattern  
between HbS and the top hit SNP. For each combination of genotypes (x-axis), I com puted the 
odds ratio  ±95% CI (y-axis). The red line shows the point of no effect.
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Region 7. A regional plot and a Forrest plot of interaction between a+thalassaemia and
rs8060012 on chromosome 16.
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R e g io n  8. A regional plot and a Forrest plot of interaction between a +thalassaem ia and 
rs3827077 on chromosome 20._________________________________________________________________
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R e g io n  9. A regional plot and a Forrest plot of interaction between a +thalassaem ia and 
rs8131755 on chromosome 21.
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The left panel shows + / -  400kb around the top hit SNP for the a 'tha lassaem ia GWIS, which had 
the smallest p-value in the region. SNPs are coloured based on their LD (r2), with the the top hit 
SNP. The -loglO P values for the SNPs are shown in I,he upper part of the plot. The bottom  
section of the plot shows the fine scale recombination rates, and genes are marked by horizontal 
blue arrows and arrowheads. The right panel is a Forrest plot showing interaction pattern  
between HbS and the top hit SNP. For each combination of genotypes (x-axis), 1 com puted the 
odds ratio ±95% CI (y-axis). The red line shows the  point of no effect.
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